Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	70.88 (8.68)	-	-	-	-
Placebo	34	70.48 (9.51)	-	-	-	-
Week 4						
MK-3102 25 mg	65	70.88 (8.68)	70.42 (10.85)	-0.47 (0.79)	0.00	-19.50 to 19.00
Placebo	34	70.48 (9.51)	69.94 (10.56)	-0.54 (1.45)	-1.25	-20.00 to 30.00
Week 8						
MK-3102 25 mg	65	70.88 (8.68)	70.80 (9.52)	-0.08 (0.65)	0.50	-17.50 to 11.70
Placebo	33	70.07 (9.35)	70.39 (11.76)	0.33 (1.24)	-0.50	-10.50 to 14.00
Week 12						
MK-3102 25 mg	64	70.88 (8.75)	69.91 (10.00)	-0.97 (0.96)	0.00	-28.80 to 11.50
Placebo	33	70.07 (9.35)	69.64 (10.72)	-0.43 (1.39)	-2.30	-10.00 to 23.00
Week 16						
MK-3102 25 mg	64	70.88 (8.75)	71.39 (10.48)	0.51 (0.86)	0.50	-13.50 to 23.00
Placebo	33	70.07 (9.35)	68.67 (10.09)	-1.40 (1.11)	-3.00	-12.00 to 15.70
Week 20						
MK-3102 25 mg	63	71.06 (8.70)	70.56 (9.73)	-0.50 (0.90)	-0.50	-19.50 to 16.00
Placebo	33	70.07 (9.35)	70.12 (9.64)	0.05 (1.10)	1.50	-12.00 to 14.70
Week 24						
MK-3102 25 mg	63	71.06 (8.70)	70.43 (10.12)	-0.63 (1.03)	-0.30	-22.50 to 23.00
Placebo	33	70.07 (9.35)	69.03 (11.43)	-1.04 (1.43)	-4.00	-14.00 to 15.50

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	70.73 (9.03)	-	-	-	-
Placebo	32	71.38 (7.55)	-	-	-	-
Week 4						
MK-3102 25 mg	67	70.73 (9.03)	71.76 (9.78)	1.04 (0.67)	0.50	-13.50 to 12.00
Placebo	32	71.38 (7.55)	70.59 (9.38)	-0.78 (1.30)	-0.90	-24.00 to 16.50
Week 8						
MK-3102 25 mg	67	70.73 (9.03)	71.60 (10.25)	0.87 (0.99)	0.00	-12.50 to 34.50
Placebo	32	71.38 (7.55)	70.78 (9.68)	-0.59 (1.40)	-1.00	-24.00 to 16.00
Week 12						
MK-3102 25 mg	67	70.73 (9.03)	72.07 (10.67)	1.35 (0.94)	0.00	-13.50 to 33.50
Placebo	30	70.97 (7.57)	69.83 (8.51)	-1.13 (1.06)	-1.00	-21.00 to 8.00
Week 16						
MK-3102 25 mg	67	70.73 (9.03)	72.09 (10.32)	1.36 (0.86)	0.70	-13.50 to 22.00
Placebo	30	70.97 (7.57)	69.17 (9.64)	-1.80 (1.34)	-1.25	-18.00 to 14.00
Week 20						
MK-3102 25 mg	67	70.73 (9.03)	71.75 (8.92)	1.02 (0.79)	-0.30	-11.80 to 22.50
Placebo	29	70.45 (7.15)	68.83 (8.08)	-1.62 (1.45)	-1.30	-22.00 to 16.50
Week 24						
MK-3102 25 mg	67	70.73 (9.03)	71.63 (10.43)	0.90 (0.99)	0.70	-14.50 to 32.50
Placebo	29	70.45 (7.15)	69.93 (9.16)	-0.52 (1.41)	-2.50	-20.00 to 23.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	65.91 (11.33)	-	-	-	-
Placebo	63	65.17 (9.38)	-	-	-	-
Week 24						
MK-3102 25 mg	124	65.84 (11.23)	65.81 (10.70)	-0.02 (0.72)	0.00	-22.00 to 47.00
Placebo	63	65.17 (9.38)	64.71 (10.68)	-0.46 (0.94)	-1.00	-27.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	65.54 (11.89)	-	-	-	-
Placebo	34	67.35 (10.87)	-	-	-	-
Week 24						
MK-3102 25 mg	63	64.89 (10.85)	65.27 (9.10)	0.38 (1.14)	1.00	-35.00 to 14.00
Placebo	33	67.76 (10.78)	66.00 (9.96)	-1.76 (1.83)	-1.00	-31.00 to 18.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	66.61 (7.75)	-	-	-	-
Placebo	33	63.70 (9.03)	-	-	-	-
Week 24						
MK-3102 25 mg	66	66.61 (7.75)	67.00 (9.20)	0.39 (0.77)	0.50	-14.00 to 14.00
Placebo	33	63.70 (9.03)	63.91 (9.05)	0.21 (1.14)	0.00	-11.00 to 18.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	65.52 (10.25)	-	-	-	-
Placebo	33	64.79 (10.59)	-	-	-	-
Week 24						
MK-3102 25 mg	65	65.52 (10.25)	66.09 (10.45)	0.57 (0.68)	0.00	-9.00 to 20.00
Placebo	32	64.34 (10.44)	63.13 (9.69)	-1.22 (1.32)	-1.00	-18.00 to 19.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	64.61 (9.79)	-	-	-	-
Placebo	32	63.91 (7.73)	-	-	-	-
Week 24						
MK-3102 25 mg	67	64.61 (9.79)	66.15 (9.96)	1.54 (0.94)	0.00	-12.00 to 27.00
Placebo	29	63.76 (8.10)	63.79 (10.21)	0.03 (1.22)	0.00	-11.00 to 22.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	65.91 (11.33)	-	-	-	-
Placebo	63	65.17 (9.38)	-	-	-	-
Week 24						
MK-3102 25 mg	124	65.84 (11.23)	65.81 (10.70)	-0.02 (0.72)	0.00	-22.00 to 47.00
Placebo	63	65.17 (9.38)	64.71 (10.68)	-0.46 (0.94)	-1.00	-27.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	65.54 (11.89)	-	-	-	-
Placebo	34	67.24 (10.75)	-	-	-	-
Week 24						
MK-3102 25 mg	63	64.89 (10.85)	65.27 (9.10)	0.38 (1.14)	1.00	-35.00 to 14.00
Placebo	33	67.64 (10.66)	66.06 (10.05)	-1.58 (1.85)	-1.00	-31.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	66.61 (7.75)	-	-	-	-
Placebo	33	63.70 (9.03)	-	-	-	-
Week 24						
MK-3102 25 mg	66	66.61 (7.75)	67.00 (9.20)	0.39 (0.77)	0.50	-14.00 to 14.00
Placebo	33	63.70 (9.03)	63.91 (9.05)	0.21 (1.14)	0.00	-11.00 to 18.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	65.52 (10.25)	-	-	-	-
Placebo	34	65.41 (11.04)	-	-	-	-
Week 24						
MK-3102 25 mg	65	65.52 (10.25)	66.09 (10.45)	0.57 (0.68)	0.00	-9.00 to 20.00
Placebo	33	65.00 (10.95)	63.36 (9.64)	-1.64 (1.35)	-1.00	-18.00 to 19.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	64.61 (9.79)	-	-	-	-
Placebo	32	63.91 (7.73)	-	-	-	-
Week 24						
MK-3102 25 mg	67	64.61 (9.79)	66.15 (9.96)	1.54 (0.94)	0.00	-12.00 to 27.00
Placebo	29	63.76 (8.10)	63.79 (10.21)	0.03 (1.22)	0.00	-11.00 to 22.00

C Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	933.62 (166.24)	-	-	-	-
Placebo	63	935.21 (136.02)	-	-	-	-
Week 24						
MK-3102 25 mg	124	934.31 (165.68)	928.48 (150.34)	-5.82 (9.64)	-7.50	-660.00 to 253.00
Placebo	63	935.21 (136.02)	950.19 (154.14)	14.98 (12.52)	17.00	-277.00 to 271.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	936.86 (153.55)	-	-	-	-
Placebo	34	910.62 (140.72)	-	-	-	-
Week 24						
MK-3102 25 mg	63	943.27 (148.31)	929.54 (125.85)	-13.73 (14.69)	-20.00	-221.00 to 379.00
Placebo	33	904.55 (138.30)	919.39 (131.74)	14.85 (23.82)	9.00	-249.00 to 341.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	907.02 (102.82)	-	-	-	-
Placebo	33	951.76 (123.43)	-	-	-	-
Week 24						
MK-3102 25 mg	66	907.02 (102.82)	905.39 (127.20)	-1.62 (11.97)	-11.00	-280.00 to 229.00
Placebo	33	951.76 (123.43)	948.52 (128.04)	-3.24 (15.94)	-5.00	-220.00 to 165.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	933.12 (142.76)	-	-	-	-
Placebo	34	941.32 (177.01)	-	-	-	-
Week 24						
MK-3102 25 mg	65	933.12 (142.76)	926.55 (144.00)	-6.57 (9.65)	-5.00	-268.00 to 200.00
Placebo	33	946.85 (176.75)	964.79 (155.09)	17.94 (16.23)	6.00	-169.00 to 231.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	943.79 (137.31)	-	-	-	-
Placebo	32	939.28 (117.84)	-	-	-	-
Week 24						
MK-3102 25 mg	67	943.79 (137.31)	916.30 (139.42)	-27.49 (14.73)	0.00	-560.00 to 168.00
Placebo	29	943.03 (122.34)	955.21 (129.12)	12.17 (15.51)	7.00	-168.00 to 180.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	166.66 (21.51)	-	-	-	-
Placebo	63	166.40 (20.19)	-	-	-	-
Week 24						
MK-3102 25 mg	123	166.92 (21.64)	168.02 (20.55)	1.10 (0.88)	1.00	-32.00 to 30.00
Placebo	62	167.15 (19.46)	168.79 (18.52)	1.65 (1.23)	1.50	-19.00 to 38.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	163.54 (20.66)	-	-	-	-
Placebo	33	164.61 (18.20)	-	-	-	-
Week 24						
MK-3102 25 mg	62	162.85 (20.53)	165.39 (21.39)	2.53 (1.20)	2.00	-17.00 to 27.00
Placebo	32	164.63 (18.49)	164.25 (17.80)	-0.38 (1.53)	-0.50	-21.00 to 25.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	166.17 (22.59)	-	-	-	-
Placebo	33	164.12 (22.13)	-	-	-	-
Week 24						
MK-3102 25 mg	66	166.17 (22.59)	166.17 (21.41)	0.00 (1.18)	0.00	-20.00 to 30.00
Placebo	33	164.12 (22.13)	160.61 (22.21)	-3.52 (2.43)	-1.00	-60.00 to 12.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	164.38 (18.98)	-	-	-	-
Placebo	33	179.00 (25.52)	-	-	-	-
Week 24						
MK-3102 25 mg	65	164.38 (18.98)	163.94 (20.64)	-0.45 (1.97)	0.00	-87.00 to 32.00
Placebo	32	178.97 (25.92)	177.31 (23.16)	-1.66 (1.74)	-1.50	-32.00 to 17.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	163.42 (21.13)	-	-	-	-
Placebo	32	164.97 (20.96)	-	-	-	-
Week 24						
MK-3102 25 mg	67	163.42 (21.13)	164.70 (19.79)	1.28 (1.66)	1.00	-44.00 to 58.00
Placebo	29	163.69 (21.37)	163.28 (24.60)	-0.41 (2.15)	-2.00	-21.00 to 44.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	99.47 (17.92)	-	-	-	-
Placebo	63	100.03 (16.72)	-	-	-	-
Week 24						
MK-3102 25 mg	124	99.64 (18.01)	98.98 (18.80)	-0.66 (0.43)	0.00	-14.00 to 12.00
Placebo	63	100.03 (16.72)	98.32 (16.25)	-1.71 (1.06)	-1.00	-60.00 to 9.00

C Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	96.06 (10.55)	-	-	-	-
Placebo	34	97.41 (11.32)	-	-	-	-
Week 24						
MK-3102 25 mg	63	96.14 (10.68)	95.49 (10.42)	-0.65 (0.60)	0.00	-20.00 to 14.00
Placebo	33	96.55 (10.29)	96.12 (10.88)	-0.42 (0.85)	-1.00	-8.00 to 14.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	98.70 (18.30)	-	-	-	-
Placebo	33	93.73 (11.67)	-	-	-	-
Week 24						
MK-3102 25 mg	66	98.70 (18.30)	98.11 (19.09)	-0.59 (0.51)	0.00	-15.00 to 12.00
Placebo	33	93.73 (11.67)	93.12 (10.51)	-0.61 (0.77)	0.00	-17.00 to 13.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	96.17 (14.65)	-	-	-	-
Placebo	34	99.65 (16.36)	-	-	-	-
Week 24						
MK-3102 25 mg	65	96.17 (14.65)	94.57 (16.14)	-1.60 (0.78)	-1.00	-38.00 to 9.00
Placebo	33	100.06 (16.43)	99.67 (16.43)	-0.39 (0.70)	0.00	-10.00 to 8.00

C Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	99.31 (18.85)	-	-	-	-
Placebo	32	93.28 (14.97)	-	-	-	-
Week 24						
MK-3102 25 mg	67	99.31 (18.85)	97.85 (17.50)	-1.46 (0.84)	0.00	-35.00 to 15.00
Placebo	29	92.72 (15.48)	91.76 (14.58)	-0.97 (0.90)	0.00	-13.00 to 6.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	405.21 (34.05)	-	-	-	-
Placebo	63	405.62 (29.38)	-	-	-	-
Week 24						
MK-3102 25 mg	124	405.00 (33.98)	407.46 (37.68)	2.46 (2.76)	0.00	-106.00 to 254.00
Placebo	63	405.62 (29.38)	408.52 (30.75)	2.90 (2.72)	2.00	-80.00 to 47.00

C Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	400.57 (29.42)	-	-	-	-
Placebo	34	400.88 (28.09)	-	-	-	-
Week 24						
MK-3102 25 mg	63	401.62 (29.07)	402.41 (27.85)	0.79 (2.64)	1.00	-50.00 to 56.00
Placebo	33	399.52 (27.35)	402.88 (26.69)	3.36 (4.32)	-2.00	-44.00 to 71.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	399.03 (27.08)	-	-	-	-
Placebo	33	403.06 (26.57)	-	-	-	-
Week 24						
MK-3102 25 mg	66	399.03 (27.08)	398.35 (24.53)	-0.68 (2.06)	-1.00	-34.00 to 53.00
Placebo	33	403.06 (26.57)	398.09 (23.79)	-4.97 (3.16)	-8.00	-42.00 to 30.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	399.20 (28.62)	-	-	-	-
Placebo	34	402.82 (34.99)	-	-	-	-
Week 24						
MK-3102 25 mg	65	399.20 (28.62)	401.22 (24.29)	2.02 (2.22)	0.00	-46.00 to 65.00
Placebo	33	404.55 (34.04)	405.79 (33.18)	1.24 (2.91)	0.00	-42.00 to 36.00

C Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	400.51 (30.54)	-	-	-	-
Placebo	32	403.34 (21.71)	-	-	-	-
Week 24						
MK-3102 25 mg	67	400.51 (30.54)	401.25 (31.17)	0.75 (2.33)	0.00	-62.00 to 48.00
Placebo	29	401.97 (22.03)	402.10 (23.14)	0.14 (2.41)	0.00	-35.00 to 36.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	31.17 (34.08)	-	-	-	-
Placebo	63	41.13 (35.78)	-	-	-	-
Week 24						
MK-3102 25 mg	124	31.27 (33.87)	31.76 (30.84)	0.49 (1.55)	-1.50	-29.00 to 120.00
Placebo	63	41.13 (35.78)	40.56 (36.62)	-0.57 (1.13)	-1.00	-22.00 to 33.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	40.91 (31.36)	-	-	-	-
Placebo	34	34.41 (35.62)	-	-	-	-
Week 24						
MK-3102 25 mg	63	40.98 (31.74)	39.35 (33.61)	-1.63 (1.14)	-1.00	-26.00 to 19.00
Placebo	33	33.73 (35.94)	34.48 (33.55)	0.76 (1.60)	0.00	-22.00 to 31.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	37.74 (29.16)	-	-	-	-
Placebo	33	34.85 (28.49)	-	-	-	-
Week 24						
MK-3102 25 mg	66	37.74 (29.16)	37.35 (29.11)	-0.39 (1.20)	-2.00	-18.00 to 30.00
Placebo	33	34.85 (28.49)	35.09 (29.12)	0.24 (1.36)	1.00	-14.00 to 20.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	29.03 (24.91)	-	-	-	-
Placebo	34	29.38 (31.62)	-	-	-	-
Week 24						
MK-3102 25 mg	65	29.03 (24.91)	29.69 (25.62)	0.66 (0.89)	1.00	-17.00 to 21.00
Placebo	33	30.33 (31.61)	30.15 (31.10)	-0.18 (1.55)	2.00	-21.00 to 22.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	31.42 (35.41)	-	-	-	-
Placebo	32	39.69 (28.81)	-	-	-	-
Week 24						
MK-3102 25 mg	67	31.42 (35.41)	30.30 (34.35)	-1.12 (1.90)	-3.00	-34.00 to 84.00
Placebo	29	42.55 (27.80)	44.55 (24.83)	2.00 (1.72)	2.00	-13.00 to 30.00

C Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	126	421.75 (22.94)	-	-	-	-
Placebo	63	421.06 (22.57)	-	-	-	-
Week 24						
MK-3102 25 mg	124	421.35 (22.86)	424.98 (32.80)	3.63 (2.72)	1.50	-52.00 to 297.00
Placebo	63	421.06 (22.57)	421.25 (22.46)	0.19 (1.89)	1.00	-56.00 to 31.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	416.29 (22.77)	-	-	-	-
Placebo	34	422.09 (20.59)	-	-	-	-
Week 24						
MK-3102 25 mg	63	415.68 (22.25)	418.81 (20.49)	3.13 (2.11)	1.00	-38.00 to 53.00
Placebo	33	422.06 (20.90)	421.91 (20.51)	-0.15 (2.76)	4.00	-31.00 to 25.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	66	419.91 (21.95)	-	-	-	-
Placebo	33	414.76 (23.89)	-	-	-	-
Week 24						
MK-3102 25 mg	66	419.91 (21.95)	420.52 (23.61)	0.61 (2.27)	-1.00	-40.00 to 57.00
Placebo	33	414.76 (23.89)	410.52 (23.28)	-4.24 (3.42)	0.00	-62.00 to 23.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	65	415.11 (21.95)	-	-	-	-
Placebo	34	417.47 (19.78)	-	-	-	-
Week 24						
MK-3102 25 mg	65	415.11 (21.95)	419.05 (21.08)	3.94 (2.23)	1.00	-27.00 to 95.00
Placebo	33	418.09 (19.75)	414.76 (21.28)	-3.33 (2.25)	-4.00	-30.00 to 19.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Week 0 to Week 24)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102 25 mg	67	414.00 (25.94)	-	-	-	-
Placebo	32	417.56 (20.18)	-	-	-	-
Week 24						
MK-3102 25 mg	67	414.00 (25.94)	421.69 (32.27)	7.69 (2.98)	6.00	-32.00 to 151.00
Placebo	29	415.38 (19.91)	413.41 (22.73)	-1.97 (2.34)	-1.00	-30.00 to 23.00

Confidential

付録 2.7.4: 27　　治療期 78 週時の体重変化量（kg）
（LDA モデル）（Extension FAS）（P006-13）

Confidential

Longitudinal Data Analysis of Change from Baseline in Body Weight (kg) at Week 78 (Extension FAS)

Treatment	N	Change from Baseline at Week 78 LS Mean (95% CI)
Placebo/Metformin	80	0.4 (-0.4, 1.2)
MK-3102 0.25 mg/25 mg	83	0.8 (0.0, 1.6)
MK-3102 1 mg/25 mg	91	0.3 (-0.4, 1.1)
MK-3102 3 mg/25 mg	79	-0.1 (-0.9, 0.8)
MK-3102 10 mg/25 mg	82	0.5 (-0.3, 1.3)
MK-3102 25 mg/25 mg	70	0.7 (-0.2, 1.6)

N = number of patients in the FAS population.
LS Mean = Least Square Mean
Based on a model with terms for treatment, prior AHA therapy status (yes/no), geographic region (Japan/ex-Japan), and the interaction of time by treatment, time by prior AHA therapy status

C Confidential

付録 2.7.4: 28　　治療期 52 週時の体重変化量（kg）（cLDA モデル）（FAS）（P020）

Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight (kg) at Week 52 (FAS) (Extension)

Treatment	N	Change from Baseline at Week 52 LS Mean (95% CI)†
MK3102/MK3102	166	0.37 (0.04, 0.71)
Sitagliptin/MK3102	164	0.50 (0.16, 0.84)
Placebo/MK3102	82	0.17 (-0.30, 0.64)

N = number of subjects in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a model with terms for treatment, prior AHA therapy status (yes/no), time and the interaction of time by treatment, time by prior AHA therapy status, and time by treatment by prior AHA therapy status with the constraint that the mean baseline is the same for all treatment groups.

C Confidential

付録 2.7.4: 29　　治療期 52 週時の体重変化量（kg）（cLDA モデル）（FAS）（P015）

Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight(kg) at Week 52
Subjects Having Basal Medication: Sulfonylureas (SUs)
(FAS)(Extension)

Treatment	N	Change from Baseline LS Mean (95% CI)†
MK-3102/MK-3102	126	0.55 (0.23, 0.87)
Placebo/MK-3102	63	-0.06 (-0.51, 0.40)

N = number of Subjects in corresponding basal AHA medication in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a cLDA model with terms for treatment, prior AHA therapy status except for basal medication (yes/no), time, and the interaction of time by treatment, time by prior AHA therapy status except for basal medication, time by treatment by prior AHA therapy status except for basal medication with the restriction of a common baseline mean between two treatment groups. Newton-Raphson method and unstructured variance-covariance matrix is used.

C Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight(kg) at Week 52
Subjects Having Basal Medication: Glinides
(FAS)(Extension)

Treatment	N	Change from Baseline LS Mean (95% CI)†
MK-3102/MK-3102	65	0.35 (-0.31, 1.01)
Placebo/MK-3102	34	0.95 (-0.29, 2.19)

N = number of Subjects in corresponding basal AHA medication in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a cLDA model with terms for treatment, prior AHA therapy status except for basal medication (yes/no), time, and the interaction of time by treatment, time by prior AHA therapy status except for basal medication, time by treatment by prior AHA therapy status except for basal medication with the restriction of a common baseline mean between two treatment groups. Fisher-Scoring method and unstructured variance-covariance matrix is used.

C Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight(kg) at Week 52 Subjects Having Basal Medication: Biguanides (BGs) (FAS)(Extension)

Treatment	N	Change from Baseline LS Mean (95% CI)†
MK-3102/MK-3102	66	0.53 (-0.05, 1.11)
Placebo/MK-3102	33	0.32 (-0.90, 1.54)

N = number of Subjects in corresponding basal AHA medication in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a cLDA model with terms for treatment, prior AHA therapy status except for basal medication (yes/no), time, and the interaction of time by treatment, time by prior AHA therapy status except for basal medication, time by treatment by prior AHA therapy status except for basal medication with the restriction of a common baseline mean between two treatment groups. Fisher-Scoring method and unstructured variance-covariance matrix is used.

C Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight(kg) at Week 52
Subjects Having Basal Medication: Thiazolidinediones (TZDs)
(FAS)(Extension)

Treatment	N	Change from Baseline LS Mean (95% CI)†
MK-3102/MK-3102	65	1.26 (0.40, 2.12)
Placebo/MK-3102	34	1.31 (-0.07, 2.69)

N = number of Subjects in corresponding basal AHA medication in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a cLDA model with terms for treatment, prior AHA therapy status except for basal medication (yes/no), time, and the interaction of time by treatment, time by prior AHA therapy status except for basal medication, time by treatment by prior AHA therapy status except for basal medication with the restriction of a common baseline mean between two treatment groups. Fisher-Scoring method and unstructured variance-covariance matrix is used.

C Confidential

Constrained Longitudinal Data Analysis of Change from Baseline in Weight(kg) at Week 52 Subjects Having Basal Medication: α-glucosidase inhibitors (α-GIs) (FAS)(Extension)

Treatment	N	Change from Baseline LS Mean (95% CI)†
MK-3102/MK-3102	67	0.42 (-0.11, 0.95)
Placebo/MK-3102	32	-1.19 (-1.97, -0.42)


N = number of Subjects in corresponding basal AHA medication in the FAS population for each treatment.
LS Mean = Least Squares Mean.
† Based on a cLDA model with terms for treatment, prior AHA therapy status except for basal medication (yes/no), time, and the interaction of time by treatment, time by prior AHA therapy status except for basal medication, time by treatment by prior AHA therapy status except for basal medication with the restriction of a common baseline mean between two treatment groups. Fisher-Scoring method and unstructured variance-covariance matrix is used.

C Confidential

付録 2.7.4: 30　　血圧、脈拍、及び QTc 間隔の経時推移
（安全性解析対象集団）
（P020）

C Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0.641	-0.593	-0.981	-0.93	-0.772	-2.227
Sitagliptin 50 mg	0	-1.06	-0.162	-0.895	-1.125	-1.71	-1.864
Placebo	0	0.2939	-0.133	-0.426	-0.636	-0.974	-1.424

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0 078	-0 024	-0.412	-0 354	-0.16	-1.611	-0.566	-0.075	0.0645	0 8993	1.4414

Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(Sitagliptin/MK-3102)



Change from Baseline(Mean)						
Sitagliptin/MK-3102	0	0.925	1.2	0.6646	1.4503	2.034

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0.1	0 55	0 3165	1 9091	1.7237

C Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0.752	-2.441	-2.659	-2.71	-1.998	-3.69
Sitagliptin 50 mg	0	-2.017	-1.132	-1.611	-2.989	-3.414	-2.666
Placebo	0	-0.185	0.3024	-2.198	-0.634	-2.371	-3.059

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0.1506	-1.533	-1.752	-1 829	-1.067	-2.759	-2.038	-1 56	-0 355	0.8859	2.5448

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(Sitagliptin/MK-3102)




Change from Baseline(Mean)						
Sitagliptin/MK-3102	0	0.2531	0 5406	0.788	1 9536	3 8503

Treatment Arms: Sitagliptin/MK-3102

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
(Mean +/- SE)
(ASaT) (Extension)
(Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0.175	1.25	1.4177	3.2078	2.4211

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0 0988	-0.07	0.6327	-0.124	-0.316	0.2438
Sitagliptin 50 mg	0	-0.273	-0.099	-0.149	0 205	0.0781	0.0062
Placebo	0	0.6012	0.028	0.7232	-0.159	-0.671	0.4788

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
(Mean +/- SE)
(ASaT) (Extension)
(MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0.096	-0.242	0.4606	-0.287	-0.448	0.1173	-0.585	-0.453	0.1161	-0.148	0.1448

Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
(Mean +/- SE)
(ASaT) (Extension)
(Sitagliptin/MK-3102)



Change from Baseline(Mean)						
Sitagliptin/MK-3102	0	0.2219	0.0344	-0.617	0.4768	0.7551

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
(Mean +/- SE)
(ASaT) (Extension)
(Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0 0875	-0.238	-0 899	-0.169	1.4342


C Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
(Mean +/- SE)
(ASaT) (Extension)
(MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-1.331	-0.836


Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
(Mean +/- SE)
(ASaT) (Extension)
(Sitagliptin/MK-3102)



C Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
(Mean +/- SE)
(ASaT) (Extension)
(Placebo/MK-3102)



Change from Baseline(Mean)

Placebo/MK-3102	0	3.925

C Confidential

付録 2.7.4: 31　　バイタルサイン及び心電図検査項目のベースラインからの変化量
（安全性解析対象集団）
（P020、長期投与時）

Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	66.75 (12.92)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	66.75 (12.92)	66.85 (12.93)	0.09 (0.08)	0.10	-2.80 to 3.00
Week 8						
MK-3102/MK-3102	165	66.74 (12.96)	66.88 (13.02)	0.14 (0.10)	0.20	-3.60 to 4.40
Week 12						
MK-3102/MK-3102	165	66.74 (12.96)	66.78 (12.96)	0.04 (0.12)	0.10	-5.60 to 6.80
Week 16						
MK-3102/MK-3102	164	66.70 (12.98)	66.81 (13.07)	0.11 (0.13)	0.20	-7.00 to 8.80
Week 20						
MK-3102/MK-3102	163	66.69 (13.02)	66.73 (13.14)	0.04 (0.15)	0.10	-6.40 to 9.20
Week 24						
MK-3102/MK-3102	162	66.70 (13.06)	66.76 (13.23)	0.06 (0.17)	0.30	-8.50 to 8.70
Week 28						
MK-3102/MK-3102	159	66.69 (13.18)	66.65 (13.21)	-0.03 (0.17)	-0.10	-8.90 to 9.40
Week 32						
MK-3102/MK-3102	159	66.69 (13.18)	66.81 (13.32)	0.12 (0.18)	0.10	-8.90 to 8.80
Week 36						
MK-3102/MK-3102	155	66.66 (13.16)	66.77 (13.19)	0.11 (0.18)	0.20	-8.10 to 8.70
Week 44						
MK-3102/MK-3102	149	66.43 (13.27)	66.70 (13.34)	0.26 (0.17)	0.20	-7.80 to 8.00

C Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 52						
MK-3102/MK-3102	145	65.87 (12.62)	66.28 (12.60)	0.41 (0.17)	0.40	-7.40 to 7.50

Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	68.77 (13.80)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	68.77 (13.80)	68.77 (13.85)	0.00 (0.07)	0.05	-2.40 to 2.50
Week 32						
Sitagliptin/MK-3102	160	68.77 (13.80)	68.90 (13.93)	0.13 (0.09)	0.20	-3.20 to 3.60
Week 36						
Sitagliptin/MK-3102	158	68.92 (13.80)	69.19 (13.87)	0.27 (0.10)	0.20	-3.40 to 3.60
Week 44						
Sitagliptin/MK-3102	151	68.26 (13.47)	68.72 (13.65)	0.47 (0.12)	0.40	-6.40 to 5.00
Week 52						
Sitagliptin/MK-3102	147	68.57 (13.39)	69.11 (13.57)	0.54 (0.14)	0.40	-6.30 to 5.00

C Confidential

Summary of Change From Baseline by Week in Weight (kg) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	64.38 (11.74)	-	-	-	-
Week 28						
Placebo/MK-3102	80	64.38 (11.74)	64.55 (11.75)	0.17 (0.09)	0.20	-2.00 to 2.50
Week 32						
Placebo/MK-3102	80	64.38 (11.74)	64.64 (11.83)	0.26 (0.12)	0.30	-2.20 to 3.20
Week 36						
Placebo/MK-3102	79	64.27 (11.78)	64.86 (11.86)	0.59 (0.14)	0.50	-2.50 to 4.00
Week 44						
Placebo/MK-3102	77	63.84 (11.45)	64.66 (11.49)	0.82 (0.16)	0.70	-4.30 to 4.40
Week 52						
Placebo/MK-3102	76	63.87 (11.53)	64.64 (11.73)	0.77 (0.20)	0.80	-5.20 to 4.40

Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	74.72 (8.82)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	74.72 (8.82)	74.64 (9.24)	-0.08 (0.55)	0.00	-21.00 to 25.00
Week 8						
MK-3102/MK-3102	165	74.63 (8.77)	74.61 (10.23)	-0.02 (0.61)	0.00	-22.00 to 20.00
Week 12						
MK-3102/MK-3102	165	74.63 (8.77)	74.22 (9.85)	-0.41 (0.52)	0.00	-22.00 to 18.00
Week 16						
MK-3102/MK-3102	164	74.61 (8.80)	74.26 (9.39)	-0.35 (0.54)	0.00	-20.00 to 16.00
Week 20						
MK-3102/MK-3102	163	74.60 (8.82)	74.44 (9.41)	-0.16 (0.59)	0.00	-20.00 to 26.00
Week 24						
MK-3102/MK-3102	162	74.57 (8.84)	72.96 (9.17)	-1.61 (0.63)	-1.00	-22.00 to 20.00
Week 28						
MK-3102/MK-3102	159	74.57 (8.78)	74.00 (9.39)	-0.57 (0.60)	-1.00	-24.00 to 21.00
Week 32						
MK-3102/MK-3102	159	74.57 (8.78)	74.49 (9.77)	-0.08 (0.64)	0.00	-18.00 to 26.00
Week 36						
MK-3102/MK-3102	155	74.40 (8.79)	74.46 (9.19)	0.06 (0.61)	0.00	-20.00 to 21.00
Week 44						
MK-3102/MK-3102	149	74.34 (8.82)	75.24 (9.09)	0.90 (0.61)	1.00	-18.00 to 24.00

Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 52						
MK-3102/MK-3102	145	74.13 (8.84)	75.57 (9.52)	1.44 (0.61)	0.00	-19.00 to 26.00

Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	74.79 (9.24)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	74.79 (9.24)	75.72 (9.06)	0.93 (0.52)	1.00	-16.00 to 26.00
Week 32						
Sitagliptin/MK-3102	160	74.79 (9.24)	75.99 (9.71)	1.20 (0.55)	1.50	-16.00 to 19.00
Week 36						
Sitagliptin/MK-3102	158	74.87 (9.26)	75.54 (8.62)	0.66 (0.64)	1.00	-29.00 to 21.00
Week 44						
Sitagliptin/MK-3102	151	74.91 (9.28)	76.36 (9.13)	1.45 (0.63)	1.00	-33.00 to 21.00
Week 52						
Sitagliptin/MK-3102	147	74.98 (9.30)	77.01 (8.90)	2.03 (0.60)	1.00	-18.00 to 18.00

C Confidential

Summary of Change From Baseline by Week in Diastolic Blood Pressure (mmHg) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	73.38 (9.88)	-	-	-	-
Week 28						
Placebo/MK-3102	80	73.38 (9.88)	73.48 (10.01)	0.10 (0.79)	1.00	-23.00 to 13.00
Week 32						
Placebo/MK-3102	80	73.38 (9.88)	73.93 (9.05)	0.55 (0.79)	0.00	-19.00 to 22.00
Week 36						
Placebo/MK-3102	79	73.34 (9.94)	73.66 (9.17)	0.32 (0.85)	0.00	-25.00 to 15.00
Week 44						
Placebo/MK-3102	77	73.06 (9.88)	74.97 (9.55)	1.91 (0.86)	1.00	-19.00 to 27.00
Week 52						
Placebo/MK-3102	76	73.08 (9.95)	74.80 (9.18)	1.72 (0.84)	1.50	-20.00 to 19.00

C Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	126.57 (14.33)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	126.57 (14.33)	126.72 (14.78)	0.15 (0.97)	2.00	-36.00 to 44.00
Week 8						
MK-3102/MK-3102	165	126.45 (14.28)	124.92 (14.63)	-1.53 (0.92)	-1.00	-32.00 to 28.00
Week 12						
MK-3102/MK-3102	165	126.45 (14.28)	124.70 (14.25)	-1.75 (0.92)	-2.00	-37.00 to 37.00
Week 16						
MK-3102/MK-3102	164	126.50 (14.31)	124.67 (13.66)	-1.83 (0.90)	-1.50	-54.00 to 38.00
Week 20						
MK-3102/MK-3102	163	126.41 (14.31)	125.34 (14.37)	-1.07 (0.99)	-2.00	-38.00 to 31.00
Week 24						
MK-3102/MK-3102	162	126.34 (14.33)	123.58 (13.76)	-2.76 (0.93)	-2.00	-32.00 to 24.00
Week 28						
MK-3102/MK-3102	159	126.36 (14.44)	124.32 (13.38)	-2.04 (0.90)	-2.00	-38.00 to 31.00
Week 32						
MK-3102/MK-3102	159	126.36 (14.44)	124.80 (13.48)	-1.56 (1.01)	-2.00	-31.00 to 33.00
Week 36						
MK-3102/MK-3102	155	126.21 (14.53)	125.86 (14.09)	-0.35 (0.97)	0.00	-34.00 to 32.00
Week 44						
MK-3102/MK-3102	149	126.11 (14.63)	127.00 (15.07)	0.89 (1.02)	2.00	-30.00 to 42.00

C Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 52						
MK-3102/MK-3102	145	126.06 (14.66)	128.61 (14.65)	2.54 (1.05)	3.00	-39.00 to 38.00

Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	125.23 (12.54)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	125.23 (12.54)	125.48 (12.64)	0.25 (0.82)	0.00	-36.00 to 25.00
Week 32						
Sitagliptin/MK-3102	160	125.23 (12.54)	125.77 (13.18)	0.54 (0.85)	0.00	-28.00 to 39.00
Week 36						
Sitagliptin/MK-3102	158	125.15 (12.54)	125.94 (12.90)	0.79 (0.94)	1.00	-40.00 to 40.00
Week 44						
Sitagliptin/MK-3102	151	125.37 (12.43)	127.32 (13.61)	1.95 (0.97)	2.00	-32.00 to 39.00
Week 52						
Sitagliptin/MK-3102	147	125.22 (12.53)	129.07 (12.26)	3.85 (0.96)	4.00	-26.00 to 32.00

Confidential

Summary of Change From Baseline by Week in Systolic Blood Pressure (mmHg) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	121.59 (15.52)	-	-	-	-
Week 28						
Placebo/MK-3102	80	121.59 (15.52)	121.76 (13.65)	0.18 (1.26)	0.00	-28.00 to 29.00
Week 32						
Placebo/MK-3102	80	121.59 (15.52)	122.84 (13.13)	1.25 (1.22)	0.50	-26.00 to 33.00
Week 36						
Placebo/MK-3102	79	121.70 (15.59)	123.11 (13.22)	1.42 (1.31)	2.00	-33.00 to 38.00
Week 44						
Placebo/MK-3102	77	121.86 (15.58)	125.06 (14.33)	3.21 (1.50)	4.00	-29.00 to 44.00
Week 52						
Placebo/MK-3102	76	121.72 (15.64)	124.14 (13.72)	2.42 (1.35)	4.00	-33.00 to 25.00

Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	70.88 (11.13)	-	-	-	-
Week 4						
MK-3102/MK-3102	166	70.88 (11.13)	70.78 (9.24)	-0.10 (0.57)	0.00	-26.00 to 22.00
Week 8						
MK-3102/MK-3102	165	70.81 (11.12)	70.56 (9.45)	-0.24 (0.56)	0.00	-26.00 to 22.00
Week 12						
MK-3102/MK-3102	165	70.81 (11.12)	71.27 (10.15)	0.46 (0.58)	0.00	-20.00 to 33.00
Week 16						
MK-3102/MK-3102	164	70.90 (11.09)	70.62 (9.68)	-0.29 (0.64)	0.00	-30.00 to 23.00
Week 20						
MK-3102/MK-3102	163	70.85 (11.10)	70.40 (9.18)	-0.45 (0.62)	0.00	-22.00 to 24.00
Week 24						
MK-3102/MK-3102	162	70.81 (11.12)	70.93 (9.87)	0.12 (0.59)	0.00	-22.00 to 18.00
Week 28						
MK-3102/MK-3102	159	70.87 (11.21)	70.29 (9.45)	-0.58 (0.62)	0.00	-26.00 to 28.00
Week 32						
MK-3102/MK-3102	159	70.87 (11.21)	70.42 (9.99)	-0.45 (0.61)	0.00	-21.00 to 27.00
Week 36						
MK-3102/MK-3102	155	70.45 (10.80)	70.56 (9.65)	0.12 (0.68)	0.00	-26.00 to 20.00
Week 44						
MK-3102/MK-3102	149	70.52 (10.86)	70.38 (9.80)	-0.15 (0.68)	0.00	-27.00 to 27.00

C Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 52						
MK-3102/MK-3102	145	69.99 (10.27)	70.13 (9.47)	0.14 (0.65)	0.00	-26.00 to 25.00

Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	70.53 (8.97)	-	-	-	-
Week 28						
Sitagliptin/MK-3102	160	70.53 (8.97)	70.76 (9.27)	0.22 (0.45)	0.00	-13.00 to 31.00
Week 32						
Sitagliptin/MK-3102	160	70.53 (8.97)	70.57 (9.01)	0.03 (0.52)	0.00	-18.00 to 32.00
Week 36						
Sitagliptin/MK-3102	158	70.66 (8.95)	70.04 (9.16)	-0.62 (0.53)	0.00	-23.00 to 18.00
Week 44						
Sitagliptin/MK-3102	151	70.27 (8.92)	70.75 (9.04)	0.48 (0.60)	0.00	-15.00 to 29.00
Week 52						
Sitagliptin/MK-3102	147	70.09 (8.96)	70.84 (9.39)	0.76 (0.60)	0.00	-25.00 to 23.00

C Confidential

Summary of Change From Baseline by Week in Pulse Rate (beats/min) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	71.69 (9.66)	-	-	-	-
Week 28						
Placebo/MK-3102	80	71.69 (9.66)	71.78 (10.14)	0.09 (0.82)	0.00	-33.00 to 15.00
Week 32						
Placebo/MK-3102	80	71.69 (9.66)	71.45 (10.43)	-0.24 (0.83)	0.00	-19.00 to 22.00
Week 36						
Placebo/MK-3102	79	71.75 (9.71)	70.85 (10.60)	-0.90 (0.74)	0.00	-18.00 to 15.00
Week 44						
Placebo/MK-3102	77	71.57 (9.70)	71.40 (8.55)	-0.17 (0.82)	0.00	-19.00 to 18.00
Week 52						
Placebo/MK-3102	76	71.96 (9.14)	73.39 (9.91)	1.43 (0.83)	0.00	-16.00 to 22.00

Confidential

Summary of Change From Baseline by Week in Atrial Rate (beats/min) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	165	65.50 (10.60)	-	-	-	-
Week 24						
MK-3102/MK-3102	165	65.50 (10.60)	65.63 (9.91)	0.13 (0.54)	0.00	-23.00 to 16.00
Week 52						
MK-3102/MK-3102	158	65.45 (10.66)	65.90 (9.98)	0.45 (0.64)	0.00	-25.00 to 20.00

C Confidential

Summary of Change From Baseline by Week in Atrial Rate (beats/min) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	65.41 (9.52)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	65.34 (9.51)	66.13 (9.81)	0.79 (0.58)	0.00	-31.00 to 23.00

Confidential

Summary of Change From Baseline by Week in Atrial Rate (beats/min) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	64.90 (9.23)	-	-	-	-
Week 52						
Placebo/MK-3102	80	64.90 (9.23)	67.01 (10.17)	2.11 (0.85)	1.50	-16.00 to 24.00

Confidential

Summary of Change From Baseline by Week in Ventricular Rate (beats/min) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	65.75 (11.08)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	65.75 (11.08)	65.83 (10.22)	0.08 (0.54)	0.00	-23.00 to 16.00
Week 52						
MK-3102/MK-3102	159	65.71 (11.15)	66.04 (10.11)	0.33 (0.65)	0.00	-25.00 to 20.00

C Confidential

Summary of Change From Baseline by Week in Ventricular Rate (beats/min) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	65.41 (9.52)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	65.34 (9.51)	66.13 (9.81)	0.79 (0.58)	0.00	-31.00 to 23.00

Confidential

Summary of Change From Baseline by Week in Ventricular Rate (beats/min) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	64.90 (9.23)	-	-	-	-
Week 52						
Placebo/MK-3102	80	64.90 (9.23)	67.01 (10.17)	2.11 (0.85)	1.50	-16.00 to 24.00

Confidential

Summary of Change From Baseline by Week in RR Interval (msec) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	929.72 (144.26)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	929.72 (144.26)	926.84 (133.96)	-2.88 (7.25)	0.00	-309.00 to 245.00
Week 52						
MK-3102/MK-3102	159	930.22 (143.91)	924.73 (136.45)	-5.49 (8.41)	-8.00	-396.00 to 280.00

Confidential

Summary of Change From Baseline by Week in RR Interval (msec) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	929.49 (134.51)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	930.43 (134.40)	918.84 (138.69)	-11.59 (8.19)	-6.00	-280.00 to 500.00

Confidential

Summary of Change From Baseline by Week in RR Interval (msec) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	937.10 (137.01)	-	-	-	-
Week 52						
Placebo/MK-3102	80	937.10 (137.01)	908.05 (134.34)	-29.05 (11.24)	-22.00	-267.00 to 190.00

Confidential

Summary of Change From Baseline by Week in PR Interval (msec) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	165.81 (21.11)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	165.81 (21.11)	167.01 (22.51)	1.20 (0.88)	0.00	-36.00 to 42.00
Week 52						
MK-3102/MK-3102	158	165.35 (20.72)	167.63 (22.07)	2.28 (0.87)	2.00	-26.00 to 48.00

Confidential

Summary of Change From Baseline by Week in PR Interval (msec) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	159	167.13 (22.02)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	156	166.72 (21.74)	166.07 (21.41)	-0.65 (0.94)	0.00	-70.00 to 30.00

Confidential

Summary of Change From Baseline by Week in PR Interval (msec) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	168.21 (23.39)	-	-	-	-
Week 52						
Placebo/MK-3102	80	168.21 (23.39)	167.13 (24.67)	-1.09 (1.24)	-1.50	-50.00 to 29.00

Confidential

Summary of Change From Baseline by Week in QRS Interval (msec) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	97.41 (12.60)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	97.41 (12.60)	97.49 (12.59)	0.08 (0.41)	0.00	-26.00 to 24.00
Week 52						
MK-3102/MK-3102	159	97.41 (12.65)	97.36 (14.01)	-0.04 (0.49)	0.00	-37.00 to 26.00

Confidential

Summary of Change From Baseline by Week in QRS Interval (msec) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	97.18 (15.18)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	97.23 (15.21)	97.82 (16.38)	0.58 (0.59)	0.00	-24.00 to 61.00

Confidential

Summary of Change From Baseline by Week in QRS Interval (msec) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	97.84 (15.69)	-	-	-	-
Week 52						
Placebo/MK-3102	80	97.84 (15.69)	97.76 (15.22)	-0.08 (0.46)	0.00	-18.00 to 16.00

Confidential

Summary of Change From Baseline by Week in QT Interval (msec) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	404.12 (29.15)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	404.12 (29.15)	402.40 (27.88)	-1.72 (1.44)	-2.00	-62.00 to 52.00
Week 52						
MK-3102/MK-3102	159	404.43 (29.49)	402.75 (29.04)	-1.67 (1.64)	-2.00	-70.00 to 61.00

Confidential

Summary of Change From Baseline by Week in QT Interval (msec) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	403.13 (27.47)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	403.35 (27.42)	401.55 (28.90)	-1.80 (1.66)	-4.00	-56.00 to 83.00

Confidential

Summary of Change From Baseline by Week in QT Interval (msec) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	405.96 (29.51)	-	-	-	-
Week 52						
Placebo/MK-3102	80	405.96 (29.51)	403.08 (29.19)	-2.89 (1.98)	-3.50	-56.00 to 40.00

Confidential

Summary of Change From Baseline by Week in QRS Axis (degrees) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	37.72 (29.42)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	37.72 (29.42)	38.16 (28.30)	0.44 (0.81)	0.00	-36.00 to 79.00
Week 52						
MK-3102/MK-3102	159	37.67 (29.74)	38.06 (29.76)	0.39 (0.84)	-1.00	-32.00 to 53.00

Confidential

Summary of Change From Baseline by Week in QRS Axis (degrees) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	32.11 (32.50)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	32.01 (32.58)	31.63 (33.44)	-0.38 (0.85)	0.00	-51.00 to 45.00

Confidential

Summary of Change From Baseline by Week in QRS Axis (degrees) (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	34.35 (27.91)	-	-	-	-
Week 52						
Placebo/MK-3102	80	34.35 (27.91)	35.38 (29.64)	1.03 (1.08)	0.00	-28.00 to 38.00

Confidential

Summary of Change From Baseline by Week in QTc Interval Bazett (msec) (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	166	421.16 (22.49)	-	-	-	-
Week 24						
MK-3102/MK-3102	166	421.16 (22.49)	419.83 (22.37)	-1.33 (1.15)	-1.00	-56.00 to 39.00
Week 52						
MK-3102/MK-3102	159	421.33 (22.29)	420.50 (19.69)	-0.84 (1.15)	1.00	-59.00 to 51.00

Confidential

Summary of Change From Baseline by Week in QTc Interval Bazett (msec) (ASaT) (Extension) (Sitagliptin/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Sitagliptin/MK-3102	160	420.13 (25.30)	-	-	-	-
Week 52						
Sitagliptin/MK-3102	159	420.14 (25.38)	421.18 (28.96)	1.04 (1.72)	0.00	-72.00 to 98.00

Confidential

Summary of Change From Baseline by Week in QTc Interval Bazett (msec) (ASaT) (Extension) (Placebo/MK-3102)


Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	80	420.91 (20.70)	-	-	-	-
Week 52						
Placebo/MK-3102	80	420.91 (20.70)	424.84 (23.30)	3.93 (1.85)	4.00	-32.00 to 49.00

Confidential

付録 2.7.4: 32　　血圧、脈拍、及び QTc 間隔の経時推移
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015）

Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0.1603	0 2296	-0.359	-0 927	-1 399	-0.588
Placebo	0	-0 678	-0 614	-1.36	-1.154	-0 826	-1.358

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0.1603	0 2296	-0 359	-0 927	-1 399	-0.588	-0.743	-1 072	0.0941	-0 288	0 2313

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0 3279	1.7833	2.4746	0 3091	0.6364

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0 22	0 22	0.7129	-0.771	-0.771	-1.095
Placebo	0	0 0794	-0 803	-0.303	-3 039	-1 994	-0.961

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0 22	0.22	0.7129	-0.771	-0.771	-1.095	-2.095	-2 341	-1 882	-1.4	-0 924

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)						
Placebo/MK-3102	0	-3.774	-1	-2.129	0.1667	-1.033

Treatment Arms: Placebo/MK-3102

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)




Change from Baseline(Mean)

MK-3102 25 mg	0	-0.736	-0 842	-0.327	-0 812	-1 289	-1.812
Placebo	0	-1.139	-3 018	-2.048	-2 897	-2 079	-1.533

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0.736	-0.842	-0.327	-0.812	-1.289	-1.812	-1.735	-1.083	-0.411	1.1516	0.1203

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	-1.788	-1 061	2 5455	1 3333	3.0625

Treatment Arms: Placebo/MK-3102

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)




Change from Baseline(Mean)							
MK-3102 25 mg	0	0.14	-0 337	-1.923	-0 814	-1 652	-2.065
Placebo	0	0 3382	-0.47	0.5909	0.4697	-2 348	-1.167

Treatment Arms: MK-3102 25 mg　Placebo

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0.14	-0.337	-1.923	-0 814	-1 652	-2.065	-1.033	-0 37	-0 843	0 84	-0 277

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	-0.182	0 303	1 5455	1 5313	0.7813

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0.14	-0 678	-0.991	-1 051	-1 991	-3.872
Placebo	0	-0 556	-0 619	-0.11	-0 877	-2 034	-2.31

Confidential


Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)



Change from Baseline(Mean)												
MK-3102/MK-3102	0	-0.14	-0.678	-0.991	-1 051	-1 991	-3.872	-3.215	-2 558	-1.439	-0.741	0.4169

Confidential

Change from Baseline Over Time in Continuous Parameters
- Diastolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0 8214	0 6429	0.1071	1 8929	2.9643

C Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0 375	-1 078	-2.124	-3 308	-3.458	-2.942
Placebo	0	-0.133	-2 625	0.3429	-1 911	-0 934	-2.676

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0 375	-1.078	-2.124	-3 308	-3.458	-2.942	-2.18	-2.784	-0 357	-0.442	0 5179

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	1 8197	1 9833	2 2881	4.4	4

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0.4123	-1 803	-0.832	-3 348	-1 848	-1.993
Placebo	0	-0 6	0.1059	-2.835	-4 8	-3 981	-4.723

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0.4123	-1.803	-0.832	-3 348	-1 848	-1.993	-3.961	-4 895	-2.748	-1 038	1.7712

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	-1 806	1 0323	0 6774	3 2667	3

C Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-1 555	-3 07	-2.327	-4.497	-4 343	-3.343
Placebo	0	-0 397	-5.427	-5.336	-6 033	-4 579	-3.245

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)



Change from Baseline(Mean)											
MK-3102/MK-3102	0	-1 555	-3.07	-2.327	-4.497	-4 343	-3.343	-5.697	-3.497	-2 888	-0 044	-0 247

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)



Change from Baseline(Mean)						
Placebo/MK-3102	0	-0 909	-1 606	2.1212	3.1212	4.4063

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0 872	-2 226	-2.855	-3.417	-1 829	-4.892
Placebo	0	0 2735	-1 824	-0.4	-4 673	-7 279	-2.188

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0 872	-2.226	-2.855	-3.417	-1 829	-4.892	-3.257	-3 225	-4 078	0 6717	-1 245

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	-2 515	-0 939	0.7879	2 9375	0.5313

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0 069	-0 293	-1.203	-3 293	-3.188	-6.322
Placebo	0	-3 269	-1 237	-1.62	-3 32	-4 503	-6.848

Confidential

Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0 069	-0.293	-1.203	-3 293	-3.188	-6.322	-6.412	-3 337	-3 263	-2 077	0.7185

Confidential


Change from Baseline Over Time in Continuous Parameters
- Systolic Blood Pressure (mmHg)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)



Change from Baseline(Mean)						
Placebo/MK-3102	0	1.1071	1 3214	1	5 6786	4.3214

C Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0 0111	0 6672	0.05	0.4894	-0.799	-1.348
Placebo	0	0.1762	-0.443	-0.379	-0 665	-1.474	-1.603

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0 0111	0.6672	0.05	0.4894	-0.799	-1.348	-0.725	-0.107	-0 62	0 5267	-0.438

Treatment Arms: MK-3102/MK-3102

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	0.7541	1 6167	3 5932	0 6	-0.364

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0 2431	0 8892	1.5339	1.7274	1.7274	0.182
Placebo	0	0.4971	-0 032	-0.356	0 8152	-0 584	-0.971

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0 2431	0.8892	1.5339	1.7274	1.7274	0.182	1.0508	2 2311	1 9033	1.135	2 9136

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	-0 097	1 8065	0 0323	1.4	1.0333

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	0 8182	0 697	1.4848	2 0615	1 0769	-0.092
Placebo	0	-0 055	0 5212	-0.842	-0 055	0.4	-0.236

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	0 8182	0.697	1.4848	2.0615	1 0769	-0.092	0.6923	0.1219	1 2625	0 9813	1.4813

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	2 303	0 2727	1 2727	0.4242	1.1563

Treatment Arms: Placebo/MK-3102

Confidential


Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)							
MK-3102 25 mg	0	-0.466	-0 082	-0.973	0 5109	-0 505	-0.632
Placebo	0	-0 535	0 3273	-0.43	-1.4	0 0545	-1.036

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	-0.466	-0.082	-0.973	0.5109	-0 505	-0.632	-0.663	-0 915	-1 213	-1 03	1 37

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	1.9697	0.1818	1.8485	1.6875	2.9688

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)




Change from Baseline(Mean)

MK-3102 25 mg	0	1 0358	0 8716	1.3493	1 3642	1 0209	0.9015
Placebo	0	-0.781	-0 594	-1.133	-1 8	-1 621	-0.517

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	1 0358	0.8716	1.3493	1.3642	1 0209	0 9015	1.2448	0 394	1 5284	1.703	2 3754

Confidential

Change from Baseline Over Time in Continuous Parameters
- Pulse Rate (beats/min)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)						
Placebo/MK-3102	0	-0 571	-0 571	-1 286	-0.143	-1.179

Treatment Arms: Placebo/MK-3102


Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	3 629	2 8017

C Confidential


Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Sulfonylureas (SUs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)



Change from Baseline(Mean)		
Placebo/MK-3102	0	-1.421


Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



C Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	3.127	2.6333


Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Glinides
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




C Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)			
MK-3102/MK-3102	0	0 6061	-0 815

Treatment Arms: MK-3102/MK-3102

C Confidential


Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Biguanides (BGs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)



Change from Baseline(Mean)		
Placebo/MK-3102	0	7.1515

Confidential


Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)		
MK-3102 25 mg	0	4.1429
Placebo	0	-3.333

Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	2.1692	3.2222

Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: Thiazolidinediones (TZDs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)




Change from Baseline(Mean)

Placebo/MK-3102	0	2.1515

Confidential


Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Week 0 to Week 24)



Change from Baseline(Mean)		
MK-3102 25 mg	0	7.6866
Placebo	0	-1.966

Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (MK-3102/MK-3102)




Change from Baseline(Mean)

MK-3102/MK-3102	0	5 5672	2 3385

Confidential

Change from Baseline Over Time in Continuous Parameters
- QTc Interval Bazett (msec)
Having Basal Medication: α-glucosidase inhibitors (α-GIs)
Excluding Data after Glycemic Rescue
(Mean +/- SE)
(ASaT) (Extension) (Placebo/MK-3102)



Change from Baseline(Mean)

Placebo/MK-3102	0	-1.607

Confidential

付録 2.7.4: 33　　バイタルサイン及び心電図検査項目のベースラインからの変化量
（レスキュー治療開始後のデータを除く）
（安全性解析対象集団）
（P015、長期投与時）

C Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	65.03 (11.03)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	65.03 (11.03)	65.35 (11.17)	0.32 (0.07)	0.20	-1.70 to 3.30
Week 8						
MK-3102/MK-3102	125	64.99 (11.07)	65.44 (11.31)	0.45 (0.10)	0.30	-2.40 to 4.40
Week 12						
MK-3102/MK-3102	124	65.11 (11.03)	65.49 (11.23)	0.38 (0.12)	0.25	-2.50 to 4.80
Week 16						
MK-3102/MK-3102	123	65.05 (11.05)	65.33 (11.28)	0.28 (0.13)	0.10	-3.60 to 3.90
Week 20						
MK-3102/MK-3102	122	64.85 (10.87)	65.12 (11.16)	0.27 (0.13)	0.10	-3.00 to 5.30
Week 24						
MK-3102/MK-3102	122	64.85 (10.87)	65.11 (11.28)	0.26 (0.14)	0.10	-4.20 to 5.30
Week 28						
MK-3102/MK-3102	122	64.85 (10.87)	65.21 (11.15)	0.37 (0.14)	0.30	-3.30 to 5.40
Week 32						
MK-3102/MK-3102	121	64.80 (10.90)	65.21 (11.25)	0.41 (0.15)	0.40	-3.10 to 6.40
Week 36						
MK-3102/MK-3102	118	64.37 (10.28)	64.89 (10.56)	0.52 (0.15)	0.35	-3.40 to 7.20

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	116	64.25 (10.28)	64.70 (10.62)	0.45 (0.16)	0.50	-3.50 to 4.10
Week 52						
MK-3102/MK-3102	112	64.48 (10.31)	65.13 (10.62)	0.65 (0.16)	0.65	-3.70 to 5.40

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	65.20 (13.89)	-	-	-	-
Week 28						
Placebo/MK-3102	62	65.20 (13.89)	65.69 (13.81)	0.32 (0.11)	0.40	-1.50 to 3.10
Week 32						
Placebo/MK-3102	61	65.28 (14.00)	65.91 (14.04)	0.45 (0.17)	0.40	-5.60 to 3.20
Week 36						
Placebo/MK-3102	60	64.97 (13.91)	66.13 (13.94)	0.96 (0.17)	0.80	-1.80 to 4.80
Week 44						
Placebo/MK-3102	56	65.08 (14.26)	66.29 (13.90)	1.05 (0.19)	0.90	-3.00 to 4.20
Week 52						
Placebo/MK-3102	56	65.08 (14.26)	66.33 (13.78)	1.07 (0.20)	1.20	-5.60 to 4.10

C Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	67.81 (13.34)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	67.81 (13.34)	68.07 (13.48)	0.26 (0.10)	0.20	-1.50 to 3.00
Week 8						
MK-3102/MK-3102	65	67.81 (13.34)	68.31 (13.70)	0.50 (0.15)	0.50	-2.60 to 4.40
Week 12						
MK-3102/MK-3102	62	67.52 (13.17)	67.97 (13.54)	0.45 (0.17)	0.40	-2.90 to 4.50
Week 16						
MK-3102/MK-3102	62	67.52 (13.17)	67.95 (13.58)	0.43 (0.21)	0.40	-2.90 to 5.40
Week 20						
MK-3102/MK-3102	62	67.52 (13.17)	67.97 (13.77)	0.45 (0.23)	0.50	-3.70 to 4.40
Week 24						
MK-3102/MK-3102	61	67.49 (13.28)	67.81 (13.65)	0.32 (0.21)	0.50	-4.40 to 3.60
Week 28						
MK-3102/MK-3102	61	67.49 (13.28)	67.86 (13.82)	0.37 (0.23)	0.40	-5.30 to 4.70
Week 32						
MK-3102/MK-3102	61	67.49 (13.28)	67.84 (13.94)	0.35 (0.27)	0.30	-7.50 to 5.10
Week 36						
MK-3102/MK-3102	61	67.49 (13.28)	67.79 (13.68)	0.30 (0.25)	0.20	-6.50 to 4.50

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	67.70 (13.29)	68.39 (13.83)	0.70 (0.25)	0.70	-4.50 to 5.50
Week 52						
MK-3102/MK-3102	59	67.60 (13.39)	68.29 (13.72)	0.69 (0.24)	0.40	-4.30 to 5.00

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	67.18 (13.30)	-	-	-	-
Week 28						
Placebo/MK-3102	31	67.18 (13.30)	67.27 (13.21)	0.09 (0.16)	0.20	-1.60 to 2.30
Week 32						
Placebo/MK-3102	31	67.18 (13.30)	67.63 (13.36)	0.45 (0.18)	0.60	-2.30 to 2.50
Week 36						
Placebo/MK-3102	31	67.18 (13.30)	67.64 (13.27)	0.46 (0.20)	0.60	-2.10 to 3.00
Week 44						
Placebo/MK-3102	30	67.32 (13.50)	67.84 (13.44)	0.52 (0.30)	0.65	-4.50 to 3.60
Week 52						
Placebo/MK-3102	30	67.32 (13.50)	67.97 (13.18)	0.65 (0.27)	0.80	-3.50 to 3.00

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	69.15 (14.33)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	69.15 (14.33)	69.25 (14.14)	0.10 (0.12)	0.15	-3.50 to 2.30
Week 8						
MK-3102/MK-3102	66	69.15 (14.33)	69.30 (14.27)	0.15 (0.18)	0.40	-7.00 to 3.20
Week 12						
MK-3102/MK-3102	66	69.15 (14.33)	69.13 (14.07)	-0.03 (0.21)	0.30	-6.50 to 3.00
Week 16						
MK-3102/MK-3102	65	69.20 (14.44)	69.29 (14.35)	0.09 (0.19)	0.10	-5.60 to 3.60
Week 20						
MK-3102/MK-3102	65	69.20 (14.44)	69.04 (14.25)	-0.16 (0.20)	-0.10	-5.40 to 3.20
Week 24						
MK-3102/MK-3102	65	69.20 (14.44)	69.04 (14.17)	-0.17 (0.18)	-0.10	-5.40 to 2.10
Week 28						
MK-3102/MK-3102	65	69.20 (14.44)	69.11 (14.27)	-0.09 (0.20)	0.00	-5.60 to 3.80
Week 32						
MK-3102/MK-3102	64	69.10 (14.53)	69.21 (14.36)	0.10 (0.23)	0.25	-5.40 to 4.70
Week 36						
MK-3102/MK-3102	64	69.10 (14.53)	69.21 (14.16)	0.10 (0.24)	0.15	-6.00 to 5.30

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	64	69.10 (14.53)	69.45 (14.50)	0.35 (0.24)	0.55	-5.40 to 4.70
Week 52						
MK-3102/MK-3102	64	69.10 (14.53)	69.59 (14.49)	0.49 (0.26)	0.70	-5.20 to 4.80

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	69.59 (12.55)	-	-	-	-
Week 28						
Placebo/MK-3102	33	69.59 (12.55)	69.63 (12.58)	0.04 (0.17)	0.00	-1.90 to 2.80
Week 32						
Placebo/MK-3102	33	69.59 (12.55)	69.82 (12.71)	0.23 (0.19)	0.00	-1.40 to 2.90
Week 36						
Placebo/MK-3102	33	69.59 (12.55)	70.07 (12.64)	0.48 (0.24)	0.20	-2.40 to 3.90
Week 44						
Placebo/MK-3102	33	69.59 (12.55)	70.50 (12.55)	0.91 (0.24)	0.80	-2.30 to 3.80
Week 52						
Placebo/MK-3102	32	69.08 (12.41)	69.86 (12.16)	0.78 (0.32)	0.80	-3.60 to 4.70

C Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	71.96 (13.61)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	71.96 (13.61)	72.26 (13.68)	0.30 (0.11)	0.20	-1.50 to 3.60
Week 8						
MK-3102/MK-3102	65	71.96 (13.61)	72.51 (13.91)	0.56 (0.14)	0.30	-1.20 to 4.30
Week 12						
MK-3102/MK-3102	64	71.88 (13.70)	72.58 (14.11)	0.70 (0.17)	0.65	-2.80 to 4.00
Week 16						
MK-3102/MK-3102	64	71.88 (13.70)	72.63 (14.07)	0.75 (0.18)	0.80	-3.80 to 5.00
Week 20						
MK-3102/MK-3102	63	72.12 (13.68)	72.63 (14.05)	0.51 (0.23)	0.40	-7.10 to 4.40
Week 24						
MK-3102/MK-3102	63	72.12 (13.68)	72.81 (14.15)	0.70 (0.26)	0.70	-8.50 to 4.40
Week 28						
MK-3102/MK-3102	63	72.12 (13.68)	72.81 (14.10)	0.70 (0.26)	0.90	-9.60 to 5.50
Week 32						
MK-3102/MK-3102	61	72.13 (13.55)	72.86 (13.76)	0.72 (0.32)	0.70	-12.80 to 6.50
Week 36						
MK-3102/MK-3102	60	72.29 (13.61)	73.11 (13.78)	0.82 (0.38)	1.10	-13.70 to 8.90

C Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	72.29 (13.61)	73.63 (13.85)	1.34 (0.41)	1.30	-16.90 to 10.00
Week 52						
MK-3102/MK-3102	60	72.29 (13.61)	73.60 (14.02)	1.31 (0.43)	1.20	-18.70 to 9.10

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	71.37 (12.93)	-	-	-	-
Week 28						
Placebo/MK-3102	33	71.37 (12.93)	71.50 (13.10)	0.13 (0.18)	0.20	-2.00 to 2.00
Week 32						
Placebo/MK-3102	33	71.37 (12.93)	71.92 (13.23)	0.56 (0.19)	0.50	-1.20 to 3.20
Week 36						
Placebo/MK-3102	33	71.37 (12.93)	71.87 (13.29)	0.50 (0.22)	0.30	-2.10 to 2.80
Week 44						
Placebo/MK-3102	32	71.53 (13.11)	72.76 (13.84)	1.24 (0.30)	0.95	-2.20 to 5.60
Week 52						
Placebo/MK-3102	32	71.53 (13.11)	72.74 (13.97)	1.21 (0.35)	1.00	-3.00 to 5.80

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	67.64 (12.78)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	67.64 (12.78)	67.59 (12.79)	-0.05 (0.10)	0.00	-2.00 to 1.80
Week 8						
MK-3102/MK-3102	67	67.64 (12.78)	67.69 (12.88)	0.05 (0.12)	0.00	-2.20 to 3.30
Week 12						
MK-3102/MK-3102	67	67.64 (12.78)	67.73 (12.92)	0.09 (0.16)	0.10	-4.00 to 3.10
Week 16						
MK-3102/MK-3102	67	67.64 (12.78)	67.87 (12.95)	0.23 (0.21)	0.40	-4.60 to 5.00
Week 20						
MK-3102/MK-3102	67	67.64 (12.78)	67.88 (12.95)	0.24 (0.21)	0.20	-5.30 to 4.00
Week 24						
MK-3102/MK-3102	67	67.64 (12.78)	67.72 (12.86)	0.09 (0.23)	0.00	-6.10 to 4.60
Week 28						
MK-3102/MK-3102	67	67.64 (12.78)	67.66 (13.00)	0.02 (0.25)	0.10	-6.00 to 5.50
Week 32						
MK-3102/MK-3102	67	67.64 (12.78)	67.73 (13.00)	0.09 (0.25)	0.10	-5.60 to 6.30
Week 36						
MK-3102/MK-3102	67	67.64 (12.78)	67.82 (13.03)	0.19 (0.24)	0.20	-4.60 to 5.30

C Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	66	67.59 (12.87)	67.87 (13.13)	0.28 (0.24)	0.45	-5.00 to 5.20
Week 52						
MK-3102/MK-3102	65	67.01 (12.06)	67.38 (12.22)	0.37 (0.23)	0.40	-3.90 to 4.80

Confidential

Summary of Change from Baseline by Week in Weight (kg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	62.93 (11.15)	-	-	-	-
Week 28						
Placebo/MK-3102	28	62.93 (11.15)	63.13 (11.31)	0.20 (0.17)	0.20	-1.50 to 3.10
Week 32						
Placebo/MK-3102	28	62.93 (11.15)	62.97 (11.57)	0.04 (0.22)	0.20	-2.20 to 2.30
Week 36						
Placebo/MK-3102	28	62.93 (11.15)	63.27 (11.80)	0.34 (0.29)	0.30	-3.40 to 3.90
Week 44						
Placebo/MK-3102	28	62.93 (11.15)	63.47 (11.73)	0.54 (0.30)	0.65	-3.60 to 4.20
Week 52						
Placebo/MK-3102	28	62.93 (11.15)	63.28 (11.35)	0.35 (0.42)	0.60	-6.50 to 5.40

C Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	75.20 (7.88)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	75.20 (7.88)	75.37 (8.67)	0.16 (0.50)	0.35	-13.50 to 13.00
Week 8						
MK-3102/MK-3102	125	75.22 (7.91)	75.45 (8.59)	0.23 (0.50)	0.00	-15.00 to 18.00
Week 12						
MK-3102/MK-3102	124	75.16 (7.91)	74.80 (8.98)	-0.36 (0.54)	-0.50	-20.50 to 13.70
Week 16						
MK-3102/MK-3102	123	75.28 (7.83)	74.35 (8.27)	-0.93 (0.50)	-1.30	-14.30 to 13.00
Week 20						
MK-3102/MK-3102	122	75.29 (7.86)	73.89 (8.47)	-1.40 (0.51)	-0.50	-19.50 to 14.00
Week 24						
MK-3102/MK-3102	122	75.29 (7.86)	74.70 (9.57)	-0.59 (0.61)	-0.75	-20.00 to 16.00
Week 28						
MK-3102/MK-3102	122	75.29 (7.86)	74.55 (8.97)	-0.74 (0.60)	-1.00	-16.30 to 22.00
Week 32						
MK-3102/MK-3102	121	75.32 (7.89)	74.25 (9.78)	-1.07 (0.62)	-1.00	-20.50 to 25.00
Week 36						
MK-3102/MK-3102	118	75.19 (7.94)	75.29 (9.93)	0.09 (0.63)	-0.50	-12.30 to 30.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	116	75.20 (7.94)	74.91 (9.78)	-0.29 (0.67)	-1.00	-19.50 to 33.00
Week 52						
MK-3102/MK-3102	112	75.30 (7.99)	75.54 (9.96)	0.23 (0.71)	0.50	-24.30 to 26.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	72.69 (9.54)	-	-	-	-
Week 28						
Placebo/MK-3102	62	72.69 (9.54)	73.02 (10.01)	0.33 (0.89)	0.00	-22.00 to 20.00
Week 32						
Placebo/MK-3102	61	72.47 (9.46)	74.44 (10.02)	1.78 (0.97)	0.50	-18.00 to 19.00
Week 36						
Placebo/MK-3102	60	72.39 (9.52)	75.08 (9.25)	2.47 (0.86)	2.00	-11.00 to 18.00
Week 44						
Placebo/MK-3102	56	72.22 (9.77)	72.61 (9.00)	0.31 (0.75)	1.00	-15.00 to 11.00
Week 52						
Placebo/MK-3102	56	72.22 (9.77)	72.89 (9.31)	0.64 (0.84)	0.00	-14.00 to 22.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	76.84 (8.27)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	76.84 (8.27)	77.06 (8.47)	0.22 (0.64)	0.70	-13.80 to 13.50
Week 8						
MK-3102/MK-3102	65	76.84 (8.27)	77.06 (9.35)	0.22 (0.65)	-0.30	-12.50 to 14.20
Week 12						
MK-3102/MK-3102	62	76.66 (8.06)	77.37 (9.11)	0.71 (0.73)	1.50	-12.00 to 12.20
Week 16						
MK-3102/MK-3102	62	76.66 (8.06)	75.89 (9.44)	-0.77 (0.79)	0.00	-15.30 to 13.00
Week 20						
MK-3102/MK-3102	62	76.66 (8.06)	75.89 (10.30)	-0.77 (0.86)	-0.50	-15.80 to 17.70
Week 24						
MK-3102/MK-3102	61	76.57 (8.09)	75.48 (9.27)	-1.10 (0.72)	-1.00	-15.80 to 12.50
Week 28						
MK-3102/MK-3102	61	76.57 (8.09)	74.48 (9.90)	-2.10 (0.70)	-1.80	-14.00 to 10.20
Week 32						
MK-3102/MK-3102	61	76.57 (8.09)	74.23 (9.88)	-2.34 (0.86)	-3.00	-17.00 to 16.00
Week 36						
MK-3102/MK-3102	61	76.57 (8.09)	74.69 (9.43)	-1.88 (0.88)	-0.50	-15.80 to 18.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	76.50 (8.14)	75.10 (9.08)	-1.40 (0.72)	-1.30	-14.50 to 9.50
Week 52						
MK-3102/MK-3102	59	76.62 (8.16)	75.69 (8.61)	-0.92 (0.78)	-0.30	-18.50 to 11.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	75.39 (9.77)	-	-	-	-
Week 28						
Placebo/MK-3102	31	75.39 (9.77)	71.61 (9.82)	-3.77 (1.17)	-3.00	-16.00 to 8.00
Week 32						
Placebo/MK-3102	31	75.39 (9.77)	74.39 (9.43)	-1.00 (1.35)	0.00	-19.00 to 14.00
Week 36						
Placebo/MK-3102	31	75.39 (9.77)	73.26 (8.52)	-2.13 (1.09)	-1.00	-17.00 to 8.00
Week 44						
Placebo/MK-3102	30	75.70 (9.78)	75.87 (11.63)	0.17 (1.10)	0.00	-10.00 to 14.00
Week 52						
Placebo/MK-3102	30	75.70 (9.78)	74.67 (9.50)	-1.03 (1.14)	-2.00	-14.00 to 10.00

C Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	77.21 (7.79)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	77.21 (7.79)	76.47 (8.55)	-0.74 (0.64)	-0.50	-13.00 to 12.50
Week 8						
MK-3102/MK-3102	66	77.21 (7.79)	76.36 (7.97)	-0.84 (0.75)	0.00	-15.00 to 15.50
Week 12						
MK-3102/MK-3102	66	77.21 (7.79)	76.88 (8.62)	-0.33 (0.70)	0.00	-12.30 to 20.50
Week 16						
MK-3102/MK-3102	65	77.09 (7.79)	76.28 (9.45)	-0.81 (0.90)	0.00	-20.30 to 22.50
Week 20						
MK-3102/MK-3102	65	77.09 (7.79)	75.80 (8.81)	-1.29 (0.84)	-1.50	-16.00 to 22.50
Week 24						
MK-3102/MK-3102	65	77.09 (7.79)	75.28 (9.02)	-1.81 (0.90)	-2.50	-15.50 to 20.50
Week 28						
MK-3102/MK-3102	65	77.09 (7.79)	75.35 (8.97)	-1.74 (0.79)	-2.00	-14.50 to 17.20
Week 32						
MK-3102/MK-3102	64	77.04 (7.84)	75.95 (9.69)	-1.08 (1.01)	0.00	-27.00 to 14.50
Week 36						
MK-3102/MK-3102	64	77.04 (7.84)	76.63 (9.26)	-0.41 (0.85)	0.00	-14.50 to 18.70

C Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	64	77.04 (7.84)	78.19 (9.03)	1.15 (0.70)	1.20	-12.50 to 14.50
Week 52						
MK-3102/MK-3102	64	77.04 (7.84)	77.16 (9.14)	0.12 (0.81)	0.00	-21.00 to 19.50

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	75.73 (6.41)	-	-	-	-
Week 28						
Placebo/MK-3102	33	75.73 (6.41)	73.94 (7.25)	-1.79 (1.15)	-2.00	-15.00 to 13.00
Week 32						
Placebo/MK-3102	33	75.73 (6.41)	74.67 (8.34)	-1.06 (1.08)	-1.00	-16.00 to 12.00
Week 36						
Placebo/MK-3102	33	75.73 (6.41)	78.27 (7.61)	2.55 (1.12)	4.00	-12.00 to 14.00
Week 44						
Placebo/MK-3102	33	75.73 (6.41)	77.06 (7.91)	1.33 (1.21)	0.00	-16.00 to 13.00
Week 52						
Placebo/MK-3102	32	75.59 (6.47)	78.66 (8.73)	3.06 (1.31)	3.00	-15.00 to 14.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	74.63 (7.84)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	74.63 (7.84)	74.77 (9.25)	0.14 (0.89)	0.00	-16.30 to 20.00
Week 8						
MK-3102/MK-3102	65	74.63 (7.84)	74.29 (8.72)	-0.34 (0.78)	0.00	-12.80 to 15.00
Week 12						
MK-3102/MK-3102	64	74.89 (7.60)	72.97 (8.11)	-1.92 (0.86)	-2.00	-23.00 to 15.70
Week 16						
MK-3102/MK-3102	64	74.89 (7.60)	74.08 (9.69)	-0.81 (0.78)	0.00	-16.50 to 12.00
Week 20						
MK-3102/MK-3102	63	75.02 (7.60)	73.37 (9.16)	-1.65 (0.77)	-1.80	-14.00 to 12.00
Week 24						
MK-3102/MK-3102	63	75.02 (7.60)	72.95 (9.87)	-2.07 (0.97)	-1.50	-21.50 to 15.50
Week 28						
MK-3102/MK-3102	63	75.02 (7.60)	73.98 (8.87)	-1.03 (0.89)	-1.00	-17.00 to 13.00
Week 32						
MK-3102/MK-3102	61	75.01 (7.67)	74.64 (7.93)	-0.37 (0.78)	-0.30	-17.00 to 11.50
Week 36						
MK-3102/MK-3102	60	75.13 (7.68)	74.28 (9.32)	-0.84 (0.87)	-0.25	-22.50 to 10.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	75.13 (7.68)	75.97 (9.20)	0.84 (0.95)	0.00	-20.00 to 15.50
Week 52						
MK-3102/MK-3102	60	75.13 (7.68)	74.85 (8.35)	-0.28 (0.80)	-0.50	-20.00 to 15.20

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	74.58 (9.50)	-	-	-	-
Week 28						
Placebo/MK-3102	33	74.58 (9.50)	74.39 (9.25)	-0.18 (0.86)	0.00	-7.00 to 12.00
Week 32						
Placebo/MK-3102	33	74.58 (9.50)	74.88 (9.50)	0.30 (1.50)	0.00	-20.00 to 18.00
Week 36						
Placebo/MK-3102	33	74.58 (9.50)	76.12 (9.38)	1.55 (1.42)	0.00	-14.00 to 25.00
Week 44						
Placebo/MK-3102	32	74.66 (9.64)	76.19 (8.94)	1.53 (1.53)	0.50	-18.00 to 17.00
Week 52						
Placebo/MK-3102	32	74.66 (9.64)	75.44 (9.80)	0.78 (1.45)	0.00	-20.00 to 24.00

C Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	76.35 (7.67)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	76.35 (7.67)	76.21 (9.21)	-0.14 (0.84)	0.50	-27.50 to 14.00
Week 8						
MK-3102/MK-3102	67	76.35 (7.67)	75.67 (8.40)	-0.68 (0.73)	0.00	-15.50 to 18.70
Week 12						
MK-3102/MK-3102	67	76.35 (7.67)	75.36 (9.19)	-0.99 (0.84)	-1.00	-22.50 to 17.00
Week 16						
MK-3102/MK-3102	67	76.35 (7.67)	75.30 (10.54)	-1.05 (0.80)	-0.80	-15.50 to 14.00
Week 20						
MK-3102/MK-3102	67	76.35 (7.67)	74.36 (10.10)	-1.99 (0.88)	-2.50	-20.00 to 17.00
Week 24						
MK-3102/MK-3102	67	76.35 (7.67)	72.48 (9.33)	-3.87 (0.88)	-3.00	-22.80 to 12.70
Week 28						
MK-3102/MK-3102	67	76.35 (7.67)	73.13 (9.17)	-3.21 (0.95)	-3.50	-20.00 to 20.70
Week 32						
MK-3102/MK-3102	67	76.35 (7.67)	73.79 (9.23)	-2.56 (0.90)	-2.30	-18.80 to 18.00
Week 36						
MK-3102/MK-3102	67	76.35 (7.67)	74.91 (8.75)	-1.44 (0.84)	-1.50	-15.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	66	76.48 (7.65)	75.74 (10.01)	-0.74 (0.99)	-1.05	-16.00 to 16.50
Week 52						
MK-3102/MK-3102	65	76.40 (7.68)	76.82 (10.03)	0.42 (0.91)	0.00	-14.80 to 21.00

Confidential

Summary of Change from Baseline by Week in Diastolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	71.11 (7.68)	-	-	-	-
Week 28						
Placebo/MK-3102	28	71.11 (7.68)	71.93 (9.10)	0.82 (1.07)	0.00	-10.00 to 15.00
Week 32						
Placebo/MK-3102	28	71.11 (7.68)	71.75 (8.91)	0.64 (0.97)	1.00	-10.00 to 10.00
Week 36						
Placebo/MK-3102	28	71.11 (7.68)	71.21 (9.32)	0.11 (1.10)	1.00	-14.00 to 9.00
Week 44						
Placebo/MK-3102	28	71.11 (7.68)	73.00 (8.22)	1.89 (1.23)	1.50	-16.00 to 14.00
Week 52						
Placebo/MK-3102	28	71.11 (7.68)	74.07 (10.59)	2.96 (1.20)	3.50	-13.00 to 15.00

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	130.99 (13.04)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	130.99 (13.04)	130.61 (14.23)	-0.37 (0.78)	-0.65	-33.00 to 23.00
Week 8						
MK-3102/MK-3102	125	131.00 (13.09)	129.92 (13.65)	-1.08 (0.84)	-1.30	-23.00 to 21.00
Week 12						
MK-3102/MK-3102	124	130.91 (13.10)	128.78 (14.13)	-2.12 (0.90)	-2.40	-21.50 to 31.00
Week 16						
MK-3102/MK-3102	123	131.10 (12.98)	127.79 (13.62)	-3.31 (0.92)	-4.00	-27.50 to 26.70
Week 20						
MK-3102/MK-3102	122	131.14 (13.03)	127.68 (13.65)	-3.46 (0.97)	-3.15	-35.00 to 29.00
Week 24						
MK-3102/MK-3102	122	131.14 (13.03)	128.20 (14.14)	-2.94 (0.87)	-3.50	-28.00 to 32.50
Week 28						
MK-3102/MK-3102	122	131.14 (13.03)	128.96 (13.93)	-2.18 (0.92)	-1.90	-31.00 to 32.00
Week 32						
MK-3102/MK-3102	121	131.11 (13.08)	128.32 (14.94)	-2.78 (0.98)	-4.00	-31.00 to 42.00
Week 36						
MK-3102/MK-3102	118	130.96 (13.08)	130.60 (15.27)	-0.36 (1.00)	-2.00	-23.00 to 34.70

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	116	131.08 (13.16)	130.64 (15.27)	-0.44 (1.04)	-0.30	-25.50 to 36.70
Week 52						
MK-3102/MK-3102	112	131.08 (13.33)	131.60 (14.63)	0.52 (1.00)	0.60	-24.30 to 29.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	125.05 (13.69)	-	-	-	-
Week 28						
Placebo/MK-3102	62	125.05 (13.69)	126.63 (14.55)	1.82 (1.45)	0.00	-19.00 to 41.00
Week 32						
Placebo/MK-3102	61	124.85 (13.72)	126.97 (12.90)	1.98 (1.42)	2.00	-19.00 to 25.00
Week 36						
Placebo/MK-3102	60	124.69 (13.78)	127.12 (13.86)	2.29 (1.49)	2.00	-24.00 to 34.00
Week 44						
Placebo/MK-3102	56	124.35 (13.45)	128.89 (14.65)	4.40 (1.72)	4.00	-24.00 to 38.00
Week 52						
Placebo/MK-3102	56	124.35 (13.45)	128.29 (13.12)	4.00 (1.77)	3.00	-23.00 to 35.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	129.73 (12.83)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	129.73 (12.83)	130.14 (14.48)	0.41 (1.23)	0.50	-20.30 to 28.70
Week 8						
MK-3102/MK-3102	65	129.73 (12.83)	127.92 (14.31)	-1.80 (1.15)	-2.50	-18.50 to 20.70
Week 12						
MK-3102/MK-3102	62	129.78 (12.58)	128.95 (14.04)	-0.83 (1.28)	-0.15	-20.50 to 35.70
Week 16						
MK-3102/MK-3102	62	129.78 (12.58)	126.44 (15.94)	-3.35 (1.36)	-1.65	-30.30 to 18.70
Week 20						
MK-3102/MK-3102	62	129.78 (12.58)	127.94 (15.01)	-1.85 (1.38)	-1.00	-34.50 to 23.70
Week 24						
MK-3102/MK-3102	61	129.53 (12.53)	127.54 (13.73)	-1.99 (1.19)	0.20	-22.30 to 16.00
Week 28						
MK-3102/MK-3102	61	129.53 (12.53)	125.57 (14.87)	-3.96 (1.34)	-3.80	-25.30 to 25.70
Week 32						
MK-3102/MK-3102	61	129.53 (12.53)	124.64 (14.59)	-4.90 (1.45)	-4.50	-30.30 to 23.00
Week 36						
MK-3102/MK-3102	61	129.53 (12.53)	126.79 (14.88)	-2.75 (1.54)	-1.50	-28.30 to 21.70

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	129.56 (12.63)	128.52 (13.69)	-1.04 (1.20)	-1.00	-22.00 to 39.20
Week 52						
MK-3102/MK-3102	59	129.81 (12.59)	131.58 (13.27)	1.77 (1.33)	2.70	-33.50 to 23.70

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	123.23 (14.33)	-	-	-	-
Week 28						
Placebo/MK-3102	31	123.23 (14.33)	121.42 (13.42)	-1.81 (1.91)	-1.00	-29.00 to 24.00
Week 32						
Placebo/MK-3102	31	123.23 (14.33)	124.26 (15.03)	1.03 (2.07)	-1.00	-18.00 to 32.00
Week 36						
Placebo/MK-3102	31	123.23 (14.33)	123.90 (12.04)	0.68 (1.92)	-1.00	-22.00 to 20.00
Week 44						
Placebo/MK-3102	30	123.00 (14.52)	126.27 (14.79)	3.27 (2.09)	2.00	-21.00 to 23.00
Week 52						
Placebo/MK-3102	30	123.00 (14.52)	126.00 (12.93)	3.00 (1.71)	1.50	-11.00 to 23.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	129.46 (11.29)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	129.46 (11.29)	127.91 (14.16)	-1.55 (1.20)	-1.90	-42.50 to 18.70
Week 8						
MK-3102/MK-3102	66	129.46 (11.29)	126.39 (12.70)	-3.07 (1.10)	-1.00	-25.50 to 18.50
Week 12						
MK-3102/MK-3102	66	129.46 (11.29)	127.14 (13.09)	-2.33 (1.16)	-3.00	-22.80 to 27.00
Week 16						
MK-3102/MK-3102	65	129.42 (11.38)	124.92 (12.69)	-4.50 (1.26)	-4.00	-44.80 to 20.00
Week 20						
MK-3102/MK-3102	65	129.42 (11.38)	125.08 (13.75)	-4.34 (1.29)	-3.00	-34.00 to 20.00
Week 24						
MK-3102/MK-3102	65	129.42 (11.38)	126.08 (13.78)	-3.34 (1.27)	-4.00	-25.80 to 26.50
Week 28						
MK-3102/MK-3102	65	129.42 (11.38)	123.72 (13.34)	-5.70 (1.22)	-6.00	-36.50 to 12.00
Week 32						
MK-3102/MK-3102	64	129.59 (11.38)	126.09 (13.51)	-3.50 (1.39)	-2.65	-28.50 to 31.00
Week 36						
MK-3102/MK-3102	64	129.59 (11.38)	126.70 (15.15)	-2.89 (1.48)	-3.25	-26.00 to 37.50

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	64	129.59 (11.38)	129.55 (13.46)	-0.04 (1.12)	0.85	-21.00 to 16.50
Week 52						
MK-3102/MK-3102	64	129.59 (11.38)	129.34 (12.94)	-0.25 (1.10)	-2.00	-16.50 to 23.50

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	125.09 (10.44)	-	-	-	-
Week 28						
Placebo/MK-3102	33	125.09 (10.44)	124.18 (9.50)	-0.91 (1.37)	0.00	-18.00 to 13.00
Week 32						
Placebo/MK-3102	33	125.09 (10.44)	123.48 (10.85)	-1.61 (1.39)	-2.00	-18.00 to 15.00
Week 36						
Placebo/MK-3102	33	125.09 (10.44)	127.21 (12.40)	2.12 (1.67)	2.00	-18.00 to 21.00
Week 44						
Placebo/MK-3102	33	125.09 (10.44)	128.21 (13.53)	3.12 (1.88)	2.00	-21.00 to 25.00
Week 52						
Placebo/MK-3102	32	125.44 (10.41)	129.84 (11.40)	4.41 (1.78)	6.00	-15.00 to 28.00

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	129.83 (11.64)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	129.83 (11.64)	128.95 (13.54)	-0.87 (1.46)	-0.50	-37.80 to 41.50
Week 8						
MK-3102/MK-3102	65	129.83 (11.64)	127.60 (13.10)	-2.23 (1.20)	-2.50	-27.00 to 19.50
Week 12						
MK-3102/MK-3102	64	130.07 (11.56)	127.22 (11.38)	-2.85 (1.33)	-3.25	-25.50 to 19.20
Week 16						
MK-3102/MK-3102	64	130.07 (11.56)	126.66 (12.50)	-3.42 (1.28)	-3.65	-26.80 to 17.20
Week 20						
MK-3102/MK-3102	63	130.03 (11.65)	128.21 (11.96)	-1.83 (1.19)	-0.50	-21.50 to 21.70
Week 24						
MK-3102/MK-3102	63	130.03 (11.65)	125.14 (14.50)	-4.89 (1.43)	-3.30	-27.50 to 16.20
Week 28						
MK-3102/MK-3102	63	130.03 (11.65)	126.78 (13.86)	-3.26 (1.46)	-3.00	-30.00 to 30.50
Week 32						
MK-3102/MK-3102	61	130.34 (11.56)	127.11 (12.90)	-3.22 (1.19)	-2.50	-23.00 to 15.70
Week 36						
MK-3102/MK-3102	60	130.61 (11.46)	126.53 (12.11)	-4.08 (1.36)	-1.80	-25.50 to 15.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	130.61 (11.46)	131.28 (12.08)	0.67 (1.25)	0.00	-25.80 to 29.50
Week 52						
MK-3102/MK-3102	60	130.61 (11.46)	129.37 (12.83)	-1.25 (1.39)	-2.15	-23.50 to 19.20

C Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	129.82 (13.76)	-	-	-	-
Week 28						
Placebo/MK-3102	33	129.82 (13.76)	127.30 (11.90)	-2.52 (1.70)	-1.00	-20.00 to 16.00
Week 32						
Placebo/MK-3102	33	129.82 (13.76)	128.88 (12.86)	-0.94 (1.84)	-3.00	-24.00 to 20.00
Week 36						
Placebo/MK-3102	33	129.82 (13.76)	130.61 (12.27)	0.79 (1.67)	0.00	-20.00 to 21.00
Week 44						
Placebo/MK-3102	32	130.13 (13.87)	133.06 (13.57)	2.94 (1.70)	2.00	-22.00 to 21.00
Week 52						
Placebo/MK-3102	32	130.13 (13.87)	130.66 (10.49)	0.53 (1.82)	0.50	-17.00 to 21.00

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	127.47 (10.31)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	127.47 (10.31)	127.40 (13.71)	-0.07 (1.26)	1.50	-24.50 to 32.50
Week 8						
MK-3102/MK-3102	67	127.47 (10.31)	127.18 (12.03)	-0.29 (1.16)	-1.00	-19.00 to 20.50
Week 12						
MK-3102/MK-3102	67	127.47 (10.31)	126.27 (11.67)	-1.20 (1.20)	-1.80	-23.50 to 27.00
Week 16						
MK-3102/MK-3102	67	127.47 (10.31)	124.18 (14.31)	-3.29 (1.31)	-2.50	-32.00 to 21.50
Week 20						
MK-3102/MK-3102	67	127.47 (10.31)	124.28 (12.88)	-3.19 (1.26)	-3.00	-29.50 to 21.00
Week 24						
MK-3102/MK-3102	67	127.47 (10.31)	121.15 (13.45)	-6.32 (1.41)	-6.00	-30.50 to 34.00
Week 28						
MK-3102/MK-3102	67	127.47 (10.31)	121.06 (13.17)	-6.41 (1.45)	-4.00	-47.50 to 21.00
Week 32						
MK-3102/MK-3102	67	127.47 (10.31)	124.13 (13.21)	-3.34 (1.46)	-4.00	-32.50 to 27.50
Week 36						
MK-3102/MK-3102	67	127.47 (10.31)	124.21 (12.99)	-3.26 (1.31)	-3.30	-26.50 to 29.50

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	66	127.70 (10.22)	125.62 (13.39)	-2.08 (1.33)	-2.25	-19.30 to 29.50
Week 52						
MK-3102/MK-3102	65	127.68 (10.30)	128.40 (13.44)	0.72 (1.57)	-1.00	-22.00 to 34.20

Confidential

Summary of Change from Baseline by Week in Systolic Blood Pressure (mmHg) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	115.71 (10.43)	-	-	-	-
Week 28						
Placebo/MK-3102	28	115.71 (10.43)	116.82 (12.68)	1.11 (1.80)	-1.00	-19.00 to 20.00
Week 32						
Placebo/MK-3102	28	115.71 (10.43)	117.04 (12.89)	1.32 (1.98)	0.50	-32.00 to 17.00
Week 36						
Placebo/MK-3102	28	115.71 (10.43)	116.71 (12.33)	1.00 (1.69)	1.50	-19.00 to 17.00
Week 44						
Placebo/MK-3102	28	115.71 (10.43)	121.39 (11.73)	5.68 (1.79)	3.50	-10.00 to 24.00
Week 52						
Placebo/MK-3102	28	115.71 (10.43)	120.04 (11.02)	4.32 (1.85)	6.00	-14.00 to 26.00

C Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	71.31 (10.06)	-	-	-	-
Week 4						
MK-3102/MK-3102	126	71.31 (10.06)	71.32 (10.56)	0.01 (0.49)	0.00	-16.00 to 13.00
Week 8						
MK-3102/MK-3102	125	71.30 (10.10)	71.97 (10.66)	0.67 (0.58)	0.00	-15.00 to 30.00
Week 12						
MK-3102/MK-3102	124	71.40 (10.07)	71.45 (10.68)	0.05 (0.64)	0.00	-35.00 to 19.50
Week 16						
MK-3102/MK-3102	123	71.35 (10.10)	71.84 (10.87)	0.49 (0.64)	0.00	-19.00 to 26.70
Week 20						
MK-3102/MK-3102	122	71.23 (10.06)	70.43 (9.58)	-0.80 (0.59)	-0.25	-24.00 to 14.70
Week 24						
MK-3102/MK-3102	122	71.23 (10.06)	69.89 (10.26)	-1.35 (0.61)	-1.00	-30.00 to 20.00
Week 28						
MK-3102/MK-3102	122	71.23 (10.06)	70.51 (10.51)	-0.73 (0.68)	0.00	-27.00 to 19.20
Week 32						
MK-3102/MK-3102	121	71.32 (10.05)	71.21 (11.62)	-0.11 (0.73)	0.00	-33.00 to 34.50
Week 36						
MK-3102/MK-3102	118	71.21 (10.09)	70.58 (9.63)	-0.62 (0.63)	0.00	-18.50 to 28.50

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	116	71.01 (10.04)	71.53 (9.83)	0.53 (0.56)	0.70	-18.00 to 24.00
Week 52						
MK-3102/MK-3102	112	70.90 (10.07)	70.46 (10.79)	-0.44 (0.60)	0.00	-19.50 to 17.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	69.87 (12.78)	-	-	-	-
Week 28						
Placebo/MK-3102	62	69.87 (12.78)	70.55 (11.80)	0.75 (0.88)	0.00	-21.00 to 20.00
Week 32						
Placebo/MK-3102	61	69.82 (12.88)	71.26 (9.84)	1.62 (1.21)	1.00	-28.00 to 27.00
Week 36						
Placebo/MK-3102	60	69.29 (12.31)	72.63 (10.16)	3.59 (1.28)	3.00	-28.00 to 31.00
Week 44						
Placebo/MK-3102	56	68.71 (12.03)	69.13 (8.65)	0.60 (1.64)	0.00	-24.00 to 64.00
Week 52						
Placebo/MK-3102	56	68.71 (12.03)	68.29 (10.76)	-0.36 (1.00)	0.00	-30.00 to 15.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	71.19 (9.37)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	71.19 (9.37)	71.43 (10.86)	0.24 (0.87)	0.00	-21.50 to 28.70
Week 8						
MK-3102/MK-3102	65	71.19 (9.37)	72.08 (10.25)	0.89 (0.83)	0.50	-21.50 to 18.00
Week 12						
MK-3102/MK-3102	62	71.08 (9.49)	72.61 (11.89)	1.53 (0.94)	0.50	-12.00 to 33.00
Week 16						
MK-3102/MK-3102	62	71.08 (9.49)	72.81 (10.76)	1.73 (0.93)	1.85	-17.50 to 21.00
Week 20						
MK-3102/MK-3102	62	71.08 (9.49)	72.81 (10.69)	1.73 (0.69)	2.00	-18.80 to 14.50
Week 24						
MK-3102/MK-3102	61	70.80 (9.31)	70.98 (10.15)	0.18 (0.83)	-0.30	-15.50 to 19.00
Week 28						
MK-3102/MK-3102	61	70.80 (9.31)	71.85 (10.10)	1.05 (0.85)	1.50	-15.50 to 17.00
Week 32						
MK-3102/MK-3102	61	70.80 (9.31)	73.03 (9.33)	2.23 (0.90)	2.00	-13.80 to 28.70
Week 36						
MK-3102/MK-3102	61	70.80 (9.31)	72.70 (10.07)	1.90 (0.99)	1.50	-24.50 to 21.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	70.77 (9.39)	71.90 (10.31)	1.14 (0.94)	1.00	-15.50 to 22.50
Week 52						
MK-3102/MK-3102	59	70.85 (9.45)	73.76 (9.34)	2.91 (0.82)	2.50	-10.50 to 17.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	71.74 (10.23)	-	-	-	-
Week 28						
Placebo/MK-3102	31	71.74 (10.23)	71.65 (11.43)	-0.10 (1.31)	0.00	-21.00 to 12.00
Week 32						
Placebo/MK-3102	31	71.74 (10.23)	73.55 (11.18)	1.81 (1.82)	1.00	-19.00 to 30.00
Week 36						
Placebo/MK-3102	31	71.74 (10.23)	71.77 (9.18)	0.03 (1.35)	0.00	-16.00 to 21.00
Week 44						
Placebo/MK-3102	30	71.73 (10.41)	73.13 (12.56)	1.40 (1.73)	1.00	-26.00 to 22.00
Week 52						
Placebo/MK-3102	30	71.73 (10.41)	72.77 (11.54)	1.03 (1.74)	2.00	-16.00 to 30.00

C Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	71.71 (7.04)	-	-	-	-
Week 4						
MK-3102/MK-3102	66	71.71 (7.04)	72.53 (7.38)	0.82 (0.69)	0.95	-12.30 to 14.00
Week 8						
MK-3102/MK-3102	66	71.71 (7.04)	72.41 (9.42)	0.70 (1.04)	0.10	-17.00 to 43.00
Week 12						
MK-3102/MK-3102	66	71.71 (7.04)	73.20 (8.17)	1.48 (0.82)	1.00	-17.80 to 18.00
Week 16						
MK-3102/MK-3102	65	71.74 (7.10)	73.80 (8.09)	2.06 (0.80)	2.20	-13.50 to 20.70
Week 20						
MK-3102/MK-3102	65	71.74 (7.10)	72.82 (9.14)	1.08 (0.94)	0.20	-12.00 to 32.00
Week 24						
MK-3102/MK-3102	65	71.74 (7.10)	71.65 (8.92)	-0.09 (0.77)	-0.30	-17.80 to 19.70
Week 28						
MK-3102/MK-3102	65	71.74 (7.10)	72.43 (7.70)	0.69 (0.86)	1.00	-19.80 to 14.20
Week 32						
MK-3102/MK-3102	64	71.77 (7.15)	71.89 (8.56)	0.12 (0.92)	-0.75	-17.80 to 21.70
Week 36						
MK-3102/MK-3102	64	71.77 (7.15)	73.03 (8.70)	1.26 (1.00)	0.45	-25.50 to 24.20

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	64	71.77 (7.15)	72.75 (8.05)	0.98 (0.93)	0.45	-19.50 to 18.00
Week 52						
MK-3102/MK-3102	64	71.77 (7.15)	73.25 (9.40)	1.48 (0.91)	0.75	-12.00 to 31.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	70.15 (10.52)	-	-	-	-
Week 28						
Placebo/MK-3102	33	70.15 (10.52)	72.45 (10.61)	2.30 (1.56)	1.00	-10.00 to 43.00
Week 32						
Placebo/MK-3102	33	70.15 (10.52)	70.42 (10.18)	0.27 (1.35)	0.00	-15.00 to 17.00
Week 36						
Placebo/MK-3102	33	70.15 (10.52)	71.42 (9.68)	1.27 (0.93)	2.00	-12.00 to 13.00
Week 44						
Placebo/MK-3102	33	70.15 (10.52)	70.58 (10.65)	0.42 (1.03)	0.00	-18.00 to 12.00
Week 52						
Placebo/MK-3102	32	70.00 (10.65)	71.16 (10.04)	1.16 (1.41)	2.00	-14.00 to 23.00

C Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	70.88 (8.68)	-	-	-	-
Week 4						
MK-3102/MK-3102	65	70.88 (8.68)	70.42 (10.85)	-0.47 (0.79)	0.00	-19.50 to 19.00
Week 8						
MK-3102/MK-3102	65	70.88 (8.68)	70.80 (9.52)	-0.08 (0.65)	0.50	-17.50 to 11.70
Week 12						
MK-3102/MK-3102	64	70.88 (8.75)	69.91 (10.00)	-0.97 (0.96)	0.00	-28.80 to 11.50
Week 16						
MK-3102/MK-3102	64	70.88 (8.75)	71.39 (10.48)	0.51 (0.86)	0.50	-13.50 to 23.00
Week 20						
MK-3102/MK-3102	63	71.06 (8.70)	70.56 (9.73)	-0.50 (0.90)	-0.50	-19.50 to 16.00
Week 24						
MK-3102/MK-3102	63	71.06 (8.70)	70.43 (10.12)	-0.63 (1.03)	-0.30	-22.50 to 23.00
Week 28						
MK-3102/MK-3102	63	71.06 (8.70)	70.40 (9.89)	-0.66 (0.87)	0.00	-17.50 to 17.00
Week 32						
MK-3102/MK-3102	61	70.77 (8.56)	69.85 (9.82)	-0.91 (0.83)	0.00	-16.50 to 17.00
Week 36						
MK-3102/MK-3102	60	70.81 (8.63)	69.60 (9.31)	-1.21 (0.74)	-0.50	-18.50 to 11.50

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	60	70.81 (8.63)	69.78 (10.14)	-1.03 (0.90)	-0.50	-21.50 to 13.00
Week 52						
MK-3102/MK-3102	60	70.81 (8.63)	72.18 (10.21)	1.37 (0.79)	1.50	-15.80 to 16.70

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	69.03 (11.43)	-	-	-	-
Week 28						
Placebo/MK-3102	33	69.03 (11.43)	71.00 (10.62)	1.97 (1.24)	1.00	-9.00 to 23.00
Week 32						
Placebo/MK-3102	33	69.03 (11.43)	69.21 (10.01)	0.18 (1.30)	0.00	-13.00 to 19.00
Week 36						
Placebo/MK-3102	33	69.03 (11.43)	70.88 (10.33)	1.85 (1.21)	2.00	-12.00 to 19.00
Week 44						
Placebo/MK-3102	32	69.13 (11.60)	70.81 (10.92)	1.69 (1.18)	1.00	-12.00 to 12.00
Week 52						
Placebo/MK-3102	32	69.13 (11.60)	72.09 (11.10)	2.97 (1.39)	2.00	-14.00 to 31.00

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	70.73 (9.03)	-	-	-	-
Week 4						
MK-3102/MK-3102	67	70.73 (9.03)	71.76 (9.78)	1.04 (0.67)	0.50	-13.50 to 12.00
Week 8						
MK-3102/MK-3102	67	70.73 (9.03)	71.60 (10.25)	0.87 (0.99)	0.00	-12.50 to 34.50
Week 12						
MK-3102/MK-3102	67	70.73 (9.03)	72.07 (10.67)	1.35 (0.94)	0.00	-13.50 to 33.50
Week 16						
MK-3102/MK-3102	67	70.73 (9.03)	72.09 (10.32)	1.36 (0.86)	0.70	-13.50 to 22.00
Week 20						
MK-3102/MK-3102	67	70.73 (9.03)	71.75 (8.92)	1.02 (0.79)	-0.30	-11.80 to 22.50
Week 24						
MK-3102/MK-3102	67	70.73 (9.03)	71.63 (10.43)	0.90 (0.99)	0.70	-14.50 to 32.50
Week 28						
MK-3102/MK-3102	67	70.73 (9.03)	71.97 (9.55)	1.24 (0.81)	1.00	-11.00 to 22.50
Week 32						
MK-3102/MK-3102	67	70.73 (9.03)	71.12 (9.10)	0.39 (0.81)	-0.30	-13.50 to 24.50
Week 36						
MK-3102/MK-3102	67	70.73 (9.03)	72.25 (10.41)	1.53 (0.86)	2.00	-17.50 to 18.80

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Week 44						
MK-3102/MK-3102	66	70.77 (9.09)	72.47 (10.78)	1.70 (0.86)	1.10	-14.00 to 31.50
Week 52						
MK-3102/MK-3102	65	70.50 (8.90)	72.88 (10.61)	2.38 (0.89)	3.00	-14.50 to 20.50

Confidential

Summary of Change from Baseline by Week in Pulse Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	69.93 (9.33)	-	-	-	-
Week 28						
Placebo/MK-3102	28	69.93 (9.33)	69.36 (8.25)	-0.57 (1.36)	1.00	-20.00 to 17.00
Week 32						
Placebo/MK-3102	28	69.93 (9.33)	69.36 (7.79)	-0.57 (1.07)	-1.00	-16.00 to 11.00
Week 36						
Placebo/MK-3102	28	69.93 (9.33)	68.64 (10.04)	-1.29 (1.49)	-2.00	-16.00 to 23.00
Week 44						
Placebo/MK-3102	28	69.93 (9.33)	69.79 (7.81)	-0.14 (1.60)	0.00	-28.00 to 17.00
Week 52						
Placebo/MK-3102	28	69.93 (9.33)	68.75 (8.20)	-1.18 (1.58)	0.00	-23.00 to 14.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	65.91 (11.33)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	65.84 (11.23)	65.81 (10.70)	-0.02 (0.72)	0.00	-22.00 to 47.00
Week 52						
MK-3102/MK-3102	116	65.35 (11.33)	65.97 (11.42)	0.61 (0.60)	1.00	-19.00 to 28.00

C Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	64.80 (10.83)	-	-	-	-
Week 52						
Placebo/MK-3102	58	64.09 (9.89)	64.93 (9.35)	0.89 (1.01)	2.00	-20.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	65.54 (11.89)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	64.89 (10.85)	65.27 (9.10)	0.38 (1.14)	1.00	-35.00 to 14.00
Week 52						
MK-3102/MK-3102	60	65.12 (11.05)	66.45 (9.01)	1.33 (1.04)	2.00	-26.00 to 18.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	65.94 (10.28)	-	-	-	-
Week 52						
Placebo/MK-3102	30	65.97 (10.46)	67.77 (11.71)	1.80 (1.68)	1.50	-18.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	66.61 (7.75)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	66.61 (7.75)	67.00 (9.20)	0.39 (0.77)	0.50	-14.00 to 14.00
Week 52						
MK-3102/MK-3102	65	66.63 (7.81)	68.28 (9.22)	1.65 (0.90)	1.00	-11.00 to 24.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	63.91 (9.05)	-	-	-	-
Week 52						
Placebo/MK-3102	33	63.91 (9.05)	63.97 (7.90)	0.06 (1.43)	1.00	-26.00 to 13.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	65.52 (10.25)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	65.52 (10.25)	66.09 (10.45)	0.57 (0.68)	0.00	-9.00 to 20.00
Week 52						
MK-3102/MK-3102	63	65.71 (10.29)	67.81 (11.05)	2.10 (0.78)	1.00	-8.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	32	63.13 (9.69)	-	-	-	-
Week 52						
Placebo/MK-3102	32	63.13 (9.69)	63.78 (9.75)	0.66 (0.91)	2.00	-11.00 to 8.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	64.61 (9.79)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	64.61 (9.79)	66.15 (9.96)	1.54 (0.94)	0.00	-12.00 to 27.00
Week 52						
MK-3102/MK-3102	65	64.28 (9.18)	65.55 (10.36)	1.28 (1.12)	0.00	-32.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Atrial Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	63.71 (10.39)	-	-	-	-
Week 52						
Placebo/MK-3102	28	63.71 (10.39)	63.54 (9.94)	-0.18 (1.63)	0.00	-21.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	65.91 (11.33)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	65.84 (11.23)	65.81 (10.70)	-0.02 (0.72)	0.00	-22.00 to 47.00
Week 52						
MK-3102/MK-3102	116	65.35 (11.33)	65.97 (11.42)	0.61 (0.60)	1.00	-19.00 to 28.00

C Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	64.80 (10.83)	-	-	-	-
Week 52						
Placebo/MK-3102	58	64.09 (9.89)	64.93 (9.35)	0.89 (1.01)	2.00	-20.00 to 17.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	65.54 (11.89)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	64.89 (10.85)	65.27 (9.10)	0.38 (1.14)	1.00	-35.00 to 14.00
Week 52						
MK-3102/MK-3102	60	65.12 (11.05)	66.45 (9.01)	1.33 (1.04)	2.00	-26.00 to 18.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	66.00 (10.38)	-	-	-	-
Week 52						
Placebo/MK-3102	30	66.03 (10.56)	67.43 (10.88)	1.40 (1.58)	1.50	-18.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	66.61 (7.75)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	66.61 (7.75)	67.00 (9.20)	0.39 (0.77)	0.50	-14.00 to 14.00
Week 52						
MK-3102/MK-3102	65	66.63 (7.81)	68.28 (9.22)	1.65 (0.90)	1.00	-11.00 to 24.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	63.91 (9.05)	-	-	-	-
Week 52						
Placebo/MK-3102	33	63.91 (9.05)	63.97 (7.90)	0.06 (1.43)	1.00	-26.00 to 13.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	65.52 (10.25)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	65.52 (10.25)	66.09 (10.45)	0.57 (0.68)	0.00	-9.00 to 20.00
Week 52						
MK-3102/MK-3102	63	65.71 (10.29)	67.81 (11.05)	2.10 (0.78)	1.00	-8.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	63.36 (9.64)	-	-	-	-
Week 52						
Placebo/MK-3102	33	63.36 (9.64)	64.61 (10.70)	1.24 (1.06)	2.00	-11.00 to 20.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	64.61 (9.79)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	64.61 (9.79)	66.15 (9.96)	1.54 (0.94)	0.00	-12.00 to 27.00
Week 52						
MK-3102/MK-3102	65	64.28 (9.18)	65.55 (10.36)	1.28 (1.12)	0.00	-32.00 to 26.00

Confidential

Summary of Change from Baseline by Week in Ventricular Rate (beats/min) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	63.71 (10.39)	-	-	-	-
Week 52						
Placebo/MK-3102	28	63.71 (10.39)	63.54 (9.94)	-0.18 (1.63)	0.00	-21.00 to 26.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	933.62 (166.24)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	934.31 (165.68)	928.48 (150.34)	-5.82 (9.64)	-7.50	-660.00 to 253.00
Week 52						
MK-3102/MK-3102	116	941.81 (167.75)	931.01 (162.30)	-10.80 (8.78)	-11.50	-332.00 to 207.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	949.64 (156.57)	-	-	-	-
Week 52						
Placebo/MK-3102	58	957.49 (149.84)	940.52 (126.13)	-17.32 (13.55)	-35.00	-224.00 to 220.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	936.86 (153.55)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	943.27 (148.31)	929.54 (125.85)	-13.73 (14.69)	-20.00	-221.00 to 379.00
Week 52						
MK-3102/MK-3102	60	940.82 (151.15)	909.27 (124.21)	-31.55 (13.55)	-24.00	-249.00 to 247.00

C Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	921.42 (135.80)	-	-	-	-
Week 52						
Placebo/MK-3102	30	921.37 (138.12)	905.73 (139.96)	-15.63 (19.99)	-24.00	-296.00 to 251.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	907.02 (102.82)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	907.02 (102.82)	905.39 (127.20)	-1.62 (11.97)	-11.00	-280.00 to 229.00
Week 52						
MK-3102/MK-3102	65	906.78 (103.60)	887.22 (118.97)	-19.57 (11.56)	-18.00	-220.00 to 171.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	948.52 (128.04)	-	-	-	-
Week 52						
Placebo/MK-3102	33	948.52 (128.04)	930.67 (123.46)	-17.85 (15.90)	-24.00	-188.00 to 280.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	933.12 (142.76)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	933.12 (142.76)	926.55 (144.00)	-6.57 (9.65)	-5.00	-268.00 to 200.00
Week 52						
MK-3102/MK-3102	63	930.60 (143.12)	903.14 (135.71)	-27.46 (10.82)	-15.00	-257.00 to 158.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	964.79 (155.09)	-	-	-	-
Week 52						
Placebo/MK-3102	33	964.79 (155.09)	949.82 (165.70)	-14.97 (14.22)	-38.00	-186.00 to 190.00

Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	943.79 (137.31)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	943.79 (137.31)	922.27 (128.59)	-21.52 (12.50)	0.00	-425.00 to 168.00
Week 52						
MK-3102/MK-3102	65	946.89 (133.18)	926.28 (137.93)	-20.62 (13.87)	-7.00	-430.00 to 356.00

C Confidential

Summary of Change from Baseline by Week in RR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	956.89 (131.16)	-	-	-	-
Week 52						
Placebo/MK-3102	28	956.89 (131.16)	962.79 (133.69)	5.89 (19.54)	11.00	-241.00 to 160.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	166.66 (21.51)	-	-	-	-
Week 24						
MK-3102/MK-3102	123	166.92 (21.64)	168.02 (20.55)	1.10 (0.88)	1.00	-32.00 to 30.00
Week 52						
MK-3102/MK-3102	115	167.23 (22.12)	168.25 (21.27)	1.02 (0.97)	0.00	-32.00 to 28.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	60	168.62 (18.80)	-	-	-	-
Week 52						
Placebo/MK-3102	57	169.91 (18.71)	171.00 (19.11)	0.86 (1.25)	2.00	-35.00 to 22.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	163.54 (20.66)	-	-	-	-
Week 24						
MK-3102/MK-3102	62	162.85 (20.53)	165.39 (21.39)	2.53 (1.20)	2.00	-17.00 to 27.00
Week 52						
MK-3102/MK-3102	59	162.73 (20.81)	163.02 (21.62)	0.29 (1.48)	0.00	-34.00 to 28.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	30	165.47 (17.63)	-	-	-	-
Week 52						
Placebo/MK-3102	29	164.62 (17.31)	162.45 (18.26)	-2.17 (1.45)	-1.00	-20.00 to 16.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	166.17 (22.59)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	166.17 (22.59)	166.17 (21.41)	0.00 (1.18)	0.00	-20.00 to 30.00
Week 52						
MK-3102/MK-3102	65	166.55 (22.55)	166.88 (23.93)	0.32 (1.23)	1.00	-24.00 to 34.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	160.61 (22.21)	-	-	-	-
Week 52						
Placebo/MK-3102	33	160.61 (22.21)	164.00 (20.75)	3.39 (1.58)	2.00	-10.00 to 34.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	164.38 (18.98)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	164.38 (18.98)	163.94 (20.64)	-0.45 (1.97)	0.00	-87.00 to 32.00
Week 52						
MK-3102/MK-3102	63	163.86 (19.02)	164.81 (20.47)	0.95 (1.45)	0.00	-46.00 to 38.00

C Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	32	177.31 (23.16)	-	-	-	-
Week 52						
Placebo/MK-3102	32	177.31 (23.16)	178.22 (24.41)	0.91 (1.38)	2.50	-17.00 to 20.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	163.42 (21.13)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	163.42 (21.13)	164.70 (19.79)	1.28 (1.66)	1.00	-44.00 to 58.00
Week 52						
MK-3102/MK-3102	65	163.97 (20.77)	166.28 (21.12)	2.31 (1.65)	2.00	-25.00 to 62.00

Confidential

Summary of Change from Baseline by Week in PR Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	163.14 (25.04)	-	-	-	-
Week 52						
Placebo/MK-3102	28	163.14 (25.04)	163.50 (24.76)	0.36 (2.77)	2.00	-52.00 to 23.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	99.47 (17.92)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	99.64 (18.01)	98.98 (18.80)	-0.66 (0.43)	0.00	-14.00 to 12.00
Week 52						
MK-3102/MK-3102	116	99.70 (18.11)	99.74 (19.12)	0.04 (0.40)	0.00	-12.00 to 10.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	98.20 (16.49)	-	-	-	-
Week 52						
Placebo/MK-3102	58	98.09 (17.00)	98.48 (17.29)	0.47 (1.12)	0.00	-16.00 to 54.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	96.06 (10.55)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	96.14 (10.68)	95.49 (10.42)	-0.65 (0.60)	0.00	-20.00 to 14.00
Week 52						
MK-3102/MK-3102	60	96.15 (10.94)	97.25 (11.27)	1.10 (0.63)	0.50	-12.00 to 16.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	95.90 (10.87)	-	-	-	-
Week 52						
Placebo/MK-3102	30	96.10 (11.00)	96.83 (11.54)	0.73 (0.99)	1.50	-16.00 to 10.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	98.70 (18.30)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	98.70 (18.30)	98.11 (19.09)	-0.59 (0.51)	0.00	-15.00 to 12.00
Week 52						
MK-3102/MK-3102	65	98.71 (18.45)	99.22 (18.59)	0.51 (0.56)	0.00	-11.00 to 18.00

C Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	93.12 (10.51)	-	-	-	-
Week 52						
Placebo/MK-3102	33	93.12 (10.51)	93.36 (11.65)	0.24 (0.79)	0.00	-10.00 to 11.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	96.17 (14.65)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	96.17 (14.65)	94.57 (16.14)	-1.60 (0.78)	-1.00	-38.00 to 9.00
Week 52						
MK-3102/MK-3102	63	96.22 (14.76)	96.71 (15.84)	0.49 (0.63)	0.00	-12.00 to 13.00

C Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	99.67 (16.43)	-	-	-	-
Week 52						
Placebo/MK-3102	33	99.67 (16.43)	100.12 (15.41)	0.45 (0.85)	0.00	-12.00 to 16.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	99.31 (18.85)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	99.31 (18.85)	97.85 (17.50)	-1.46 (0.84)	0.00	-35.00 to 15.00
Week 52						
MK-3102/MK-3102	65	99.63 (19.03)	99.11 (18.37)	-0.52 (0.89)	0.00	-40.00 to 23.00

Confidential

Summary of Change from Baseline by Week in QRS Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	92.11 (14.72)	-	-	-	-
Week 52						
Placebo/MK-3102	28	92.11 (14.72)	91.57 (14.28)	-0.54 (0.85)	-1.50	-10.00 to 10.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	405.21 (34.05)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	405.00 (33.98)	407.46 (37.68)	2.46 (2.76)	0.00	-106.00 to 254.00
Week 52						
MK-3102/MK-3102	116	406.58 (34.36)	407.17 (37.99)	0.59 (2.23)	0.00	-58.00 to 160.00

C Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	408.69 (31.02)	-	-	-	-
Week 52						
Placebo/MK-3102	58	409.96 (30.27)	404.31 (27.43)	-4.95 (2.46)	-4.00	-43.00 to 52.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	400.57 (29.42)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	401.62 (29.07)	402.41 (27.85)	0.79 (2.64)	1.00	-50.00 to 56.00
Week 52						
MK-3102/MK-3102	60	401.45 (29.71)	397.75 (24.42)	-3.70 (2.36)	-4.00	-38.00 to 43.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	404.19 (26.69)	-	-	-	-
Week 52						
Placebo/MK-3102	30	403.93 (27.11)	401.27 (27.56)	-2.67 (3.84)	-0.50	-49.00 to 42.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	399.03 (27.08)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	399.03 (27.08)	398.35 (24.53)	-0.68 (2.06)	-1.00	-34.00 to 53.00
Week 52						
MK-3102/MK-3102	65	399.06 (27.29)	393.26 (23.58)	-5.80 (2.19)	-5.00	-48.00 to 34.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	398.09 (23.79)	-	-	-	-
Week 52						
Placebo/MK-3102	33	398.09 (23.79)	401.30 (24.66)	3.21 (3.16)	0.00	-33.00 to 52.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	400.74 (25.38)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	400.74 (25.38)	401.22 (24.29)	0.48 (2.07)	0.00	-46.00 to 40.00
Week 52						
MK-3102/MK-3102	63	400.05 (25.44)	396.97 (24.39)	-3.08 (2.51)	0.00	-76.00 to 36.00

C Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	405.79 (33.18)	-	-	-	-
Week 52						
Placebo/MK-3102	33	405.79 (33.18)	404.24 (32.36)	-1.55 (3.02)	0.00	-35.00 to 43.00

Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	400.51 (30.54)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	400.51 (30.54)	401.25 (31.17)	0.75 (2.33)	0.00	-62.00 to 48.00
Week 52						
MK-3102/MK-3102	65	401.43 (30.26)	398.91 (31.20)	-2.52 (2.78)	2.00	-78.00 to 81.00

C Confidential

Summary of Change from Baseline by Week in QT Interval (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	401.43 (23.27)	-	-	-	-
Week 52						
Placebo/MK-3102	28	401.43 (23.27)	401.07 (19.73)	-0.36 (3.54)	0.00	-34.00 to 42.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	31.17 (34.08)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	31.27 (33.87)	31.76 (30.84)	0.49 (1.55)	-1.50	-29.00 to 120.00
Week 52						
MK-3102/MK-3102	116	31.29 (34.46)	32.30 (36.02)	1.01 (1.38)	0.00	-27.00 to 86.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	42.72 (35.14)	-	-	-	-
Week 52						
Placebo/MK-3102	58	43.47 (35.35)	43.28 (35.28)	0.84 (1.01)	0.00	-16.00 to 20.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	40.91 (31.36)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	40.98 (31.74)	39.35 (33.61)	-1.63 (1.14)	-1.00	-26.00 to 19.00
Week 52						
MK-3102/MK-3102	60	39.85 (31.17)	36.23 (32.51)	-3.62 (1.29)	-2.50	-29.00 to 16.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	36.29 (33.75)	-	-	-	-
Week 52						
Placebo/MK-3102	30	36.47 (34.31)	36.53 (33.56)	0.07 (1.37)	-3.00	-14.00 to 21.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	37.74 (29.16)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	37.74 (29.16)	37.35 (29.11)	-0.39 (1.20)	-2.00	-18.00 to 30.00
Week 52						
MK-3102/MK-3102	65	38.05 (29.28)	37.00 (30.05)	-1.05 (1.33)	-2.00	-23.00 to 33.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	35.09 (29.12)	-	-	-	-
Week 52						
Placebo/MK-3102	33	35.09 (29.12)	34.48 (28.79)	-0.61 (1.61)	0.00	-24.00 to 18.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	29.03 (24.91)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	29.03 (24.91)	29.69 (25.62)	0.66 (0.89)	1.00	-17.00 to 21.00
Week 52						
MK-3102/MK-3102	62	29.26 (25.22)	28.13 (27.12)	-1.13 (1.25)	0.00	-35.00 to 20.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	30.15 (31.10)	-	-	-	-
Week 52						
Placebo/MK-3102	33	30.15 (31.10)	30.00 (33.42)	-0.15 (1.58)	0.00	-17.00 to 20.00

Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	31.42 (35.41)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	31.42 (35.41)	30.30 (34.35)	-1.12 (1.90)	-3.00	-34.00 to 84.00
Week 52						
MK-3102/MK-3102	65	32.00 (34.67)	30.95 (37.34)	-1.05 (2.33)	-1.00	-103.00 to 84.00

C Confidential

Summary of Change from Baseline by Week in QRS Axis (degrees) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	44.93 (25.20)	-	-	-	-
Week 52						
Placebo/MK-3102	28	44.93 (25.20)	45.18 (27.40)	0.25 (1.63)	1.00	-30.00 to 14.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	126	421.75 (22.94)	-	-	-	-
Week 24						
MK-3102/MK-3102	124	421.35 (22.86)	424.98 (32.80)	3.63 (2.72)	1.50	-52.00 to 297.00
Week 52						
MK-3102/MK-3102	116	421.31 (22.65)	424.11 (25.64)	2.80 (2.00)	1.50	-58.00 to 159.00

C Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Sulfonylureas (SUs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	61	421.59 (22.22)	-	-	-	-
Week 52						
Placebo/MK-3102	58	420.93 (22.36)	418.69 (27.39)	-1.42 (2.32)	-3.00	-35.00 to 80.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	416.29 (22.77)	-	-	-	-
Week 24						
MK-3102/MK-3102	63	415.68 (22.25)	418.81 (20.49)	3.13 (2.11)	1.00	-38.00 to 53.00
Week 52						
MK-3102/MK-3102	60	416.12 (22.69)	418.75 (21.09)	2.63 (2.34)	0.50	-37.00 to 38.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Glinides Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	31	422.94 (20.23)	-	-	-	-
Week 52						
Placebo/MK-3102	30	422.73 (20.55)	423.60 (19.14)	0.87 (2.40)	-2.00	-23.00 to 29.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	66	419.91 (21.95)	-	-	-	-
Week 24						
MK-3102/MK-3102	66	419.91 (21.95)	420.52 (23.61)	0.61 (2.27)	-1.00	-40.00 to 57.00
Week 52						
MK-3102/MK-3102	65	420.02 (22.10)	419.20 (22.45)	-0.82 (1.84)	-2.00	-34.00 to 51.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Biguanides (BGs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	410.52 (23.28)	-	-	-	-
Week 52						
Placebo/MK-3102	33	410.52 (23.28)	417.67 (22.58)	7.15 (2.97)	5.00	-24.00 to 50.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	65	416.88 (20.29)	-	-	-	-
Week 24						
MK-3102/MK-3102	65	416.88 (20.29)	419.05 (21.08)	2.17 (1.75)	1.00	-27.00 to 37.00
Week 52						
MK-3102/MK-3102	63	416.75 (20.46)	419.97 (24.22)	3.22 (2.19)	1.00	-80.00 to 39.00

C Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: Thiazolidinediones (TZDs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	33	414.76 (21.28)	-	-	-	-
Week 52						
Placebo/MK-3102	33	414.76 (21.28)	416.91 (20.10)	2.15 (2.61)	3.00	-30.00 to 36.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (MK-3102/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline						
MK-3102/MK-3102	67	414.00 (25.94)	-	-	-	-
Week 24						
MK-3102/MK-3102	67	414.00 (25.94)	419.57 (28.64)	5.57 (2.04)	6.00	-32.00 to 60.00
Week 52						
MK-3102/MK-3102	65	414.12 (25.93)	416.46 (28.97)	2.34 (2.09)	3.00	-75.00 to 50.00

Confidential

Summary of Change from Baseline by Week in QTc Interval Bazett (msec) Having Basal Medication: α-glucosidase inhibitors (α-GIs) Excluding Data after Glycemic Rescue (ASaT) (Extension) (Placebo/MK-3102)

Treatment	N	Baseline Mean (SD)	Timepoint Mean (SD)	Change from Baseline at Timepoint		
				Mean (SE)	Median	Range
Baseline(Week 24)						
Placebo/MK-3102	28	412.39 (22.46)	-	-	-	-
Week 52						
Placebo/MK-3102	28	412.39 (22.46)	410.79 (20.94)	-1.61 (2.98)	-3.00	-33.00 to 26.00

C Confidential